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Legislative Mandate 
 
The following report is hereby issued pursuant to Chapter 55 of the Acts of 2015, as amended by 
Chapter 133 of the Acts of 2016 as follows: 
 
Notwithstanding any general or special law to the contrary, the secretary of health and human services, 
in collaboration with the department of public health, shall conduct or provide for an examination of the 
prescribing and treatment history, including court-ordered treatment or treatment within the criminal 
justice system, of persons in the commonwealth who suffered fatal or nonfatal opiate overdoses in 
calendar years 2013 to 2015, inclusive. Any report or supplemental reports resulting from this 
examination shall provide any data in an aggregate and de-identified format 
 
 Notwithstanding any general or special law to the contrary, to facilitate the examination, the 
department shall request, and the relevant offices and agencies shall provide, information necessary to 
complete the examination from the division of medical assistance, the executive office of public safety 
and security, the center for health information and analysis, the office of patient protection and the 
chief justice of the trial court, which may include, but shall not be limited to: data from the prescription 
drug monitoring program; the all-payer claims database; the criminal offender record information 
database; and the court activity record information. To the extent feasible, the department shall request 
data from the Massachusetts Sheriffs Association, Inc. relating to treatment within houses of correction. 
 
 Not later than 1 year from the effective date of this act, the secretary of health and human services 
shall publish a report on the findings of the examination including, but not limited to: (i) instances of 
multiple provider episodes, meaning a single patient having access to opiate prescriptions from more 
than 1 provider; (ii) instances of poly-substance access, meaning a patient having simultaneous 
prescriptions for an opiate and a benzodiazepine or for an opiate and another drug which may enhance 
the effects or the risks of drug abuse or overdose; (iii) the overall opiate prescription history of the 
individuals, including whether the individuals had access to legal prescriptions for opiate drugs at the 
time of their deaths; (iv) whether the individuals had previously undergone voluntary or involuntary 
treatment for substance addiction or behavioral health; (v) whether the individuals had attempted to 
enter but were denied access to treatment for substance addiction or behavioral health; (vi) whether 
the individuals had received past treatment for a substance overdose; (vii) whether any individuals had 
been previously detained or incarcerated and, if so, whether the individuals had received treatment 
during the detention or incarceration. 
 
The report shall be filed with the clerks of the senate and house of representatives, the house and 
senate chairs of the joint committee on mental health and substance abuse, the joint committee on 
public health, the joint committee on health care financing and the house and senate committees on 
ways and means. The secretary of health and human services may publish supplemental reports on the 
trends identified through its examination; provided, however, that any supplemental report shall be 
filed not later than July 1, 2017 and shall be filed with the clerks of the senate and house of 
  5 
representatives, the house and senate chairs of the joint committee on mental health and substance 
abuse, the joint committee on public health, the joint committee on health care financing and the house 
and senate committees on ways and means. 
 
Notwithstanding any general or special law to the contrary, the executive office of health and human 
services may contract with a non-profit or educational entity to conduct data analytics on the data set 
generated in the examination, provided that the executive office shall implement appropriate privacy 
safeguards. 
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Executive Summary 
In the twelve months since the first Chapter 55 report was released in July 2016, nearly 2,000 
Massachusetts residents have died of opioid-related overdoses. The total number of deaths has 
increased five-fold in the last 20 years, but the rate of increase of opioid-related overdose deaths was 
particularly sharp between 2013 and 2014.1 The maps below show a graphic depiction of the increasing 
and spreading opioid crisis in Massachusetts between 2011 and 2015 (the darkening area on the maps 
below). Not since the AIDS epidemic of the 1980s and 1990s has Massachusetts seen such a sharp 
increase in a single category of deaths. 
 
Increasing and Spreading Opioid-Related Overdose Death Rates in Massachusetts from 2011 to 20152 
 
                               2011               2015 
 
The characteristics of the epidemic in Massachusetts are similar to other states. What is especially 
notable is that this epidemic does not conform to the stereotypical boundaries of race, class, gender, 
and geography. Almost every community is affected. Opioid-related overdose deaths and nonfatal 
opioid-related overdoses are highest among younger males, but all population subgroups have seen 
increases in recent years. Individuals released from incarceration are also at high risk of death upon re-
entering the community, but so too are individuals experiencing homelessness, veterans, mothers with 
opioid use disorder, and individuals with serious mental illnesses.  
                                                          
1
 Accessed at http://www.mass.gov/eohhs/docs/dph/stop-addiction/current-statistics/data-brief-overdose-deaths-february-
2017.pdf on 5/19/2017. 
2
 Maps prepared by Department of Public Health and Community Medicine, Tufts University School of Medicine. In 2011, 16% 
of zip codes were in the highest risk category. By 2015, that number had increased to 46%. The full-sized maps can be examined 
in Appendix D. 
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Fighting the current opioid epidemic has been a priority of the Baker-Polito Administration since day 
one. In February 2015, Governor Baker appointed a working group to develop a plan to reduce the rate 
of opioid-related deaths in the Commonwealth. In June 2015, the Governor’s Opioid Working Group 
released 65 recommendations and a comprehensive Action Plan aimed at curbing the current opioid 
epidemic. These short- and long-term recommendations focus on prevention, intervention, treatment, 
and recovery support. Today, nearly all of these recommendations are underway, making Massachusetts 
a national leader in terms of both investments and policy.3 
 
Understanding the complexity of this epidemic with precision is imperative to respond effectively. One 
part of this response includes the passage of Chapter 55 of the Acts of 2015 (Chapter 55) by the 
Massachusetts Legislature and Governor Charles D. Baker, and its reauthorization in Chapter 133 of the 
Acts of 2016. These laws enabled an unprecedented linkage and analysis of existing data across state 
government in order to better guide policy development and programmatic decision-making. The 
findings included in this report are a result of the linkages and analyses of more than 20 administrative 
datasets.4 
 
Contained within this report are descriptions of analyses providing the state with important new insights 
into the profile of overdose-related deaths and nonfatal opioid-related overdoses and the relative risks 
faced by the Commonwealth’s diverse populations. The report is divided into three main sections:  
 
 Re-Estimating Baseline Statistics: This section provides more accurate estimates for Opioid Use 
Disorder (OUD), Nonfatal Overdose (NFO), and Opioid-Related Overdose Deaths (OROD).  
 Timeline and Influences: This section offers an initial glimpse into the length of time between 
the stages of opioid use from an individual’s perspective from initial use of prescription 
medications to fatal overdose. 
 Identifying At-Risk Populations: This section includes estimates of the risk of fatal and nonfatal 
overdose for each of seven at-risk populations including the homeless, veterans, and individuals 
diagnosed with severe mental illness. 
 
In each section, the left column contains succinct take-home messages including current status, data 
sources, and key findings and is organized for quick reference. The larger right hand area of each page 
contains more information including the background, basic methods used for conducting the analysis, 
teams involved in the analysis, and key findings for further analysis and for policy consideration. Finally, 
the appendices provide in-depth explanations and background information.  
 
 
 
                                                          
3
 Accessed at http://www.mass.gov/eohhs/docs/dph/stop-addiction/recommendations-of-the-governors-opioid-working-
group.pdf on 5/19/2017. 
4
 Administrative data refers to information collected primarily for administrative (not research) purposes. 
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Key Findings: Massachusetts 2011-2015 
In 2015, it is estimated that over 4% of persons age 11 and older in Massachusetts had opioid 
use disorder. 
Nonfatal overdoses recorded by emergency medical services (EMS), hospitals, and bystander 
interventions increased ~200% between 2011 and 2015. The total number of nonfatal overdoses 
between 2011 and 2015 exceeded 65,000. 
Almost half of the individuals who died of an opioid-related overdose during the study period 
were at one time classified as opioid naïve5 during the study period. Risk for fatal and nonfatal 
opioid overdose grows as use continues. 
Compared to the general population, those who received three months of prescribed opioids in 
2011 were 4 times as likely to die from an opioid-related overdose within one year, and 30 times 
as likely to die of an opioid-related overdose within five years. 
It is estimated that roughly one in every 25 adults has been homeless at some point between 
2011 and 2015.  The risk of opioid-related overdose death for persons who have experienced 
homelessness is up to 30 times higher than it is for the rest of the population. 
The risk of fatal opioid-related overdose is six times higher for persons diagnosed with a serious 
mental illness (SMI) and three times higher for those diagnosed with depression. 
Compared to the rest of the adult population, the opioid-related overdose death rate is 120 
times higher for persons released from prisons and jails. 
The five-year opioid-related overdose death rate of mothers with evidence of opioid use disorder 
was 321 times higher than the rate among mothers without evidence of opioid use disorder. 
 
This effort also marks a continuation of the significant collaboration between state and federal 
government, academia, the health care system, and private industry. The Chapter 55 initiative has 
clearly demonstrated that partnerships can cross governmental and non-governmental boundaries to 
quickly address a public health problem of acknowledged urgency. However, for these types of 
partnerships to become institutional and routine, it is critical to formalize relationships. Access to a 
unique dataset in a time of crisis may temporarily attract multidisciplinary partners, but sustainability is 
best assured through formalizing data governance, mutually beneficial partnerships, and a plan for 
ongoing resourcing and data maintenance. These issues must be addressed to ensure continued 
success. 
 
The Department’s ability to engage academic partners and private industry to support monitoring and 
evaluation activities will be crucial, and collaborative, data-driven efforts such as this should become 
standard practice in Massachusetts and beyond.   
                                                          
5
 To be categorized as opioid naïve, the individual’s records had to show a period of six months or more without an opioid 
prescription before their first opioid prescription. Patients excluded from the group were persons who had any advanced 
cancer (other than non-melanoma skin cancer), had a substance use disorder diagnosis in the six months preceding their first 
opioid prescription, or whose first prescription was for any buprenorphine formulation indicated for treatment of substance 
use disorder. 
  10 
Section I. Re-Estimating Baseline Statistics 
There were indications in the information gathered during the first year of Chapter 55 work that data 
collected by government agencies about the opioid crisis portrayed an incomplete picture of the scope 
of the problem. The figure below depicts this hypothesis. In the center of the diagram is the Universe of 
Known Events, consisting of data recorded in administrative data sets like medical claims, ambulance 
trip records, and death certificates about Opioid Use Disorder (OUD), Nonfatal Overdose (NFO), and 
Opioid-related overdose deaths. The fact that we are in a crisis is made clear when we look at these 
data. The scope of the crisis, however, is not. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specifically, what is unknown are the actual number of unrecorded nonfatal overdoses and the total 
number of people with OUD. If we are to improve allocation of resources for individuals with OUD, we 
need to know how many people fit this definition and where they live. If we are to improve emergency 
services for people who have nonfatal opioid overdoses, we need to know how many people have 
overdosed, how many have overdosed repeatedly, and what proportion of reversals are overseen by 
bystanders. While opioid-related deaths are recorded on death certificates, there are strong indications 
that additional deaths may also be opioid-related. Internal data patterns suggest that publically reported 
counts of opioid-related deaths may still underestimate the size of the problem and also mask the 
impact of fentanyl on the death rates. 
 
This section of the report examines the interrelationships among all the data sets to establish estimates 
for Opioid Use Disorder (OUD), Nonfatal Overdose (NFO), and Opioid-related Overdose Deaths (OROD) 
that are more internally consistent and consistent with all the relevant data. 
Opioid Use Disorder 
(OUD) 
Nonfatal 
Overdoses 
Fatal 
Overdoses 
Universe of 
Known Events 
(Recorded) 
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Section I.a Estimating the Size of the Population 
with OUD 
 
Background: The rise in opioid-related overdose death rates nationally between 
1999 and 2010 parallels the increase in consumption of opioid analgesics.6 
While this general trend applies to Massachusetts, reliable state-level numbers 
for Opioid Use Disorder (OUD) are difficult to obtain. Without citing a specific 
rate, one recent study using 2012 data suggested that the rate of opioid use 
disorder in Massachusetts was nearly one-third higher than the national rate.7 
However, opioid-related overdose deaths in Massachusetts have more than 
doubled since 2012. Given this increase, it is more important than ever to obtain 
a reliable estimate of the size of the population with OUD.  
Basic Methods: In the normal course of business, government agencies collect 
vast amounts of administrative data to track events and transactions. While the 
data is often comprehensive, there are limitations to its use. One commonly 
cited limitation of administrative data is the likelihood that some information 
recorded is incomplete.8 Events may not be captured or diagnosis codes may 
not be listed.  
Analysts used records that were linked at the individual level across more than 
10 administrative data sets. OUD is specifically coded in the All Payer Claims 
Database, Case Mix (hospital, ED and outpatient), death records, and the post 
mortem toxicology reports recorded by the Office of the Chief Medical 
Examiner. These values were used to form what was referred to as the “Gold 
Standard” measure for OUD. 
A “capture-recapture” analysis9 was used to estimate the true prevalence of 
opioid use. Individuals were identified using markers consistent with OUD in 
each Chapter 55 data source (i.e., the Gold Standard). It was assumed that this 
data was an incomplete accounting of OUD in Massachusetts. 
Data was organized in tables by age group, sex, and county. Log linear models 
were used to fit the data to markers. The final model produced aggregate 
                                                          
6
 Jones CM. Frequency of prescription pain reliever nonmedical use: 2002-2003 and 2009-2010. 
Arch Intern Med. 2012;172(16):1265-1267. 
7
 Jones CM, Campopiano M, Baldwin G, McCance-Katz E. Am J Public Health. 2015 Aug;105(8):e55-
63. doi: 10.2105/AJPH.2015.302664. 
8
 Accessed at https://archive.ahrq.gov/data/safetynet/billings.htm on 5/19/2017. 
9
 A capture-recapture analysis is often used in ecological studies to estimate the size of a 
population when data is incomplete. 
Current Status: The best 
available estimate is that 
the rate of Opioid Use 
Disorder (OUD) in MA is 
nearly one-third higher 
than the national rate.  
Data sources: 
  
 Medical claims 
 Hospital, ED, and 
outpatient data 
 Death records 
 Ambulance trips 
 Post-mortem 
Toxicology 
 Prescription Drug 
Monitoring Program 
 Substance Abuse 
Treatment 
 Birth records 
 Dept of Mental 
Health 
 Dept of Correction 
 Houses of Correction 
 Cancer Registry 
 Dept of Housing and 
Community 
Development 
 Dept of Veterans’ 
Services 
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estimates by year, county, gender, and age group. A combination of Poisson and 
zero inflated Poisson models were used to estimate the population prevalence. 
Estimates were validated by comparing projected OUD rates with rates of fatal 
opioid-related overdose deaths. 
Key Findings:  
 Using only data specifically coded for OUD, it is estimated that 
approximately 4.4% of Massachusetts residents age 11 and older have 
opioid use disorder. No single Chapter 55 data set included all 
individuals identified by the Gold Standard of OUD. Linkage was critical 
to increase accuracy. 
 The capture-recapture methodology produced annual estimates of 
OUD. There is an indication that the size of the OUD population may be 
increasing. Further study will refine these estimates. 
 
 
 
 The proportion of the OUD population dying each year from opioid-
related overdoses has nearly doubled between 2011 (0.40%) and 2015 
(0.68%). 
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Estimated OUD Population Rises Signficantly  
Between 2011-2015 
Key Finding: In 2015, over 
4% of Massachusetts 
residents age 11 and older 
had opioid use disorder. 
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 Epidemics occur in stages from growth to equilibrium to decay. The fact 
that the OUD population may still be increasing despite the fact that the 
proportion of population dying is also increasing may suggest that we 
have not yet reached the equilibrium phase. 
Recommendations for Further Analysis: 
 Develop analytic models for making estimates of OUD for individuals.  
 Compare current OUD services for demographic and geographic 
populations to determine if services should be adjusted. 
 Examine changing demographic trends to determine whether the need 
for specific services is likely to change over time.  The population in 
Massachusetts is getting older and more ethnically diverse. 
 Evaluate the impact of transitions of care for the OUD population on 
fatal and nonfatal overdose. 
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Key Finding: The 
proportion of the OUD 
population dying each year 
from opioid-related 
overdoses has nearly 
doubled between 2011 
(0.40%) and 2015 (0.68%). 
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Section I.b Estimating the Number of Nonfatal 
Overdoses (NFO) 
 
Background: Some research has estimated that there are 20 nonfatal opioid-
related overdoses (NFO) for every fatal overdose. 10 For Massachusetts, that 
would suggest that there could be 30,000-40,000 nonfatal overdoses in 2015 
alone. However, hospital, ED, and ambulance data record fewer than 20,000 
events combined. Furthermore, the 20 to 1 ratio comes from a study that is 15 
years old and predates the influx of fentanyl into drug supply system. The actual 
estimates could be either higher or lower. More recent data from Vancouver 
found that nearly half of people who die of fatal opioid-related overdose had a 
previous nonfatal overdose in the preceding five years. 11 Since death rates in 
Massachusetts have increased so markedly since 2012, 12 it is important to know 
whether nonfatal overdoses have increased at the same rate.  
Records of nonfatal overdoses capture events when illegal activity may have 
been involved. As a result, those records are most likely incomplete accountings 
of the total number of events. To complete the picture, it is important to review 
data sources to ensure that estimates for different aspects of the opioid crisis 
are logically consistent with each other. That is why the linked Chapter 55 data 
set is such a valuable resource. All known sources were brought together to 
provide this composite estimate.  
Basic Methods: Linkage is required to identify any nonfatal overdose event in 
the administrative data sets available for Chapter 55. Overdoses are captured in 
hospital and ambulance data, but those events must be linked with death 
records to determine whether the overdose was fatal or nonfatal. 
Overdose events for individuals are recorded in the Case Mix (hospital, ED and 
outpatient data), and MATRIS (ambulance trips). While the Case Mix data is 
thought to be a fairly complete accounting of NFO seen in Massachusetts 
hospitals, it is less clear that the APCD captures all NFO events for which medical 
claims are paid. MATRIS  data has known gaps. Some emergency medical 
services have failed to report required data. Also, NFOs from MATRIS are based 
on a composite of information recorded by the EMTs to produce a likely NFO 
                                                          
10
 Darke S., Mattick R. P., Degenhardt L. The ratio of non‐fatal to fatal heroin overdose. Addiction 
2003; 98: 1169–71 
11
 Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Nonfatal overdose as a risk factor 
for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 
2016;162:51-55 
12
 http://www.mass.gov/eohhs/docs/dph/stop-addiction/dph-legislative-report-chapter-55-
opioid-overdose-study-9-15-2016.pdf 
Current Status: Some 
research has estimated that 
there are 20 nonfatal 
opioid-related overdoses 
(NFO) for every fatal 
overdose. This estimate 
predates the influx of 
fentanyl into the drug 
supply system. 
Data sources: 
  
 Hospital, ED, and 
outpatient data 
 Death records 
 Ambulance trips 
 Post-mortem 
Toxicology 
 Census data (zip level) 
 Community bystander 
reversals 
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event.13 Lastly, DPH’s Bureau of Substance Abuse Services tracks some overdose 
reversals by community. However, this is also an incomplete picture of 
bystander reversals across the state. Given the variety of data sources used in 
this analysis, data linked at the individual as well as community level data was 
used to estimate the total number of NFO. Extensive de-duplication of NFO 
events was required across the different data sets.  
All sources of data were used to develop a model of NFO that yielded a 
statistically reliable annual estimate of events in the state. Final estimates of 
missing NFO data from MATRIS were computed by comparing the ratio of 
projected NFO population rates at a community level to the rate of fatal 
overdoses by community. Values for community level “undercounts” were 
recorded. Finally, bystander reversals reported by communities were added to 
the community level “undercounts” from MATRIS. 
Key Findings:  
 Reliable MATRIS data is only available starting in 2013. Ambulance trips 
due to opioid-related overdose increased by 110% in the two following 
years.14 Overdoses are counted by an algorithm that incorporates many 
different pieces of information from the trip record for each ambulance 
run. 
 
 Naloxone was administered by an EMT in roughly two of every five 
overdose events between 2013 and 2015. While the actual number of 
naloxone administrations has increased over time, the percentage of 
                                                          
13
 Data entered into MATRIS by EMTs was never intended to be diagnostic. 
14
 This number could be an overestimate since data recorded in 2013 may have more missing 
information than subsequent years. 
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Key Finding: Ambulance 
trips due to a probable 
opioid-related overdose 
increased as much as by 
110% in two years. 
Naloxone was 
administered by EMS in 
roughly 2 of every 5 of 
these overdoses. 
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opioid-related events where naloxone was administered has remained 
relatively unchanged.  
 Multiple naloxone administrations by EMTs were up 27% from 2013 to 
2015, which aligns with the time period during which the presence of 
illicit fentanyl sharply increased in the drug supply system.  
 No single Chapter 55 data set included all individuals identified with 
NFO. Linkage between data sets was critical for this analysis.  
 Nonfatal opioid overdoses increased by ~200% between 2011 and 2015. 
The total number of nonfatal overdoses between 2011 and 2015 
exceeded 65,000.15  
 
 Annual estimates for nonfatal overdoses were compared to the number 
of fatal overdoses between 2011 and 2015. The figure below shows the 
year to year changes. 
 
                                                          
15 Linking data across multiple data systems along with the use of logical estimates of missing 
data has allowed DPH to determine likely counts for nonfatal opioid overdoses between 2011 and 
2015. Nonfatal opioid overdoses in Massachusetts have increased by ~300% in four years. 
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Recommendations for Further Analysis: 
 Since many nonfatal overdoses go unrecorded, the total number, and 
geographic and demographic distributions may still be underestimated. 
To better understand these aspects of the opioid crisis, more complex 
analytic tools (e.g., machine learning) should be used to estimate the 
number and distribution of nonfatal opioid overdoses in Massachusetts. 
 A careful examination of Naloxone distribution to communities should 
be studied using the Chapter 55 data sets to determine the 
effectiveness of this program. It will also tell us whether this program is 
increasing the proportion of “lives saved” to total overdoses, and 
where to target program resources in the future. 
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Section I.c Estimating the Total Number of 
Opioid-related Overdose Deaths (OROD) 
 
Background: Nationally and in Massachusetts, fatal opioid-related overdoses 
have dramatically increased since 2000.16 In May 2017, DPH reported that there 
were at least 1,933 confirmed opioid‐related deaths in Massachusetts during 
2016.17 In comparison, there were just one‐fifth as many confirmed opioid‐
related deaths (338) in 2000.18 
  
While the number of opioid-related overdose deaths (OROD) is at the highest 
level ever, initial analyses of Chapter 55 data indicated that the reported total 
may be an undercount.19 For example, opioid overdose was the listed cause of 
death for only 49.8% of those who died the same day as the naloxone 
administration by EMS. Similarly, there was a dip in the number of opioid-
related overdose deaths for persons in their late 30’s and early 40’s. To better 
understand these unexpected results, the data was examined to determine if 
the reported numbers of OROD should be revised upward. 
 
Unlike the examination of undercounts of opioid use disorder (OUD) and 
nonfatal overdoses (NFO), undercounts of OROD are not caused by incomplete 
data. The Office of the Chief Medical Examiner (OCME) certifies virtually all 
opioid-related deaths in the state. However, the linked Chapter 55 data 
provides analysts with an opportunity to examine data patterns across many 
data sets that the OCME could not have seen at the time the cause of death was 
being certified. For example, when making a determination of the cause of 
death, the OCME cannot systematically examine treatment and prescription 
histories or other administrative records indicating long-term opioid use. These 
additional pieces of information can be used to shed light on whether there may 
be an undercount of opioid-related deaths. 
  
Basic Methods: Analysts used 253,378 linked records of deceased individuals. 
These records were linked at the individual level across eight additional 
administrative data sets. All causes of death were included. OROD for 
                                                          
16
 Accessed at http://www.mass.gov/eohhs/gov/departments/dph/stop‐addiction/current‐
statistics.html on 5/19/2017. 
17
 Accessed at http://www.mass.gov/eohhs/gov/departments/dph/stop-addiction/current-
statistics.html on 5/19/2017. 
18
 While some of the increase in opioid-related deaths could be due to more careful reporting, it is 
unlikely that increases of this magnitude are due to reporting differences over time. 
19
 Unreported data from the first Chapter 55 study showed an unusual number of deaths in 
different age groups with long histories of opioid use and treatment. This study examines the 
likelihood that some additional deaths may be opioid-related.  
Current Status: The rate of 
recorded opioid-related 
deaths and number of 
deaths are higher than ever 
in Massachusetts. In 2016, 
there were five times as 
many confirmed opioid‐
related deaths compared to 
2000. This number may still 
be an underestimate. 
Data sources: 
  
 Medical claims 
 Hospital, ED, and 
outpatient data 
 Death records 
 Ambulance trips 
 Post-mortem 
Toxicology 
 Prescription Drug 
Monitoring Program 
 Substance Abuse 
Treatment 
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individuals was coded using the Medical Examiner’s determination of cause of 
death. A predictive model was developed using 15 dependent variables. Causes 
of deaths assigned to cases that had been referred to the Medical Examiner 
were assumed to be correct. 
 
The model produced results that could be interpreted conservatively or more 
broadly. The conservative approach focused only on a narrow range of cases 
with the specific ICD 10 codes for the cause of death that were drug related, 
related to respiratory or cardiovascular conditions, or were undefined or 
unknown.20 The sum of the probabilities from the logistic model was counted as 
the additional opioid-related overdose deaths. The broader model utilized all 
cases not referred to the Medical Examiner and summed the probabilities to 
obtain an estimate of the additional opioid-related overdose deaths.  
 
Key Findings:  
 
 The percent of total opioid-related deaths by age group shows a drop 
between age 30 and 50 suggesting the possibility that deaths may have 
been undercounted. 
 
 Before estimating total deaths, opioid-related deaths were examined 
for several temporal patterns: seasonality, weekend/weekday 
differentials, and concentrations of deaths near the beginnings of 
months when benefit checks are often distributed. Approximately 20% 
more deaths occurred per day on weekends and also 20% more during 
the first 3 days of a month. There was no seasonality effect. 
                                                          
20
 The following codes were used: F11, F19, J18, J45, I11, I21, I33, I38, I49, and R99. 
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 The number of opioid-related overdose deaths coded by the Office of 
the Chief Medical Examiner more than doubled between 2011 and 
2015. Two predictive models were developed to determine if the 
“official” count was lower than what might be expected when looking 
across the breadth of Chapter 55 data.  
  
 
 These models suggest that there might be  an additional 6% to 33% 
opioid-related overdose deaths between 2011 and 2015. Model 2 
estimates were highest for 2011 (43% increase) and 2012 (42% 
increase) compared to 2015 (25% increase). 
 Since the broader model included many categories of death that were 
less related to long-term substance misuse or causes of death that were 
undefined or vague, it was felt that the re-estimate from the 
conservative model is most likely  closer to the true value for OROD. 
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Recommendations for Further Analysis: 
 A much deeper examination of undercounted opioid-related deaths 
should be undertaken. Knowledge of which demographic groups are 
misclassified more frequently than others, and whether patterns exist 
that indicate more frequent misclassification of official causes of death, 
can guide further work in this area.  
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Section II. Timeline and Influences 
 Opioid Naïve   Continued Use      Nonfatal Overdose Impact of Fentanyl  
                 
 
 
 
Introduction 
 
In addition to being able to look across many different data sets as was the case in the previous section, 
the Chapter 55 data set also allows analysts to look at individuals for up to a five year time period. There 
has been much discussion about the role of prescription medications in fueling the opioid crisis in 
Massachusetts and elsewhere. There is also growing evidence of the impact of fentanyl on the sharp 
increase in fatal and nonfatal overdoses in the state.21 While the Chapter 55 data can be used to 
establish the risk of fatal and nonfatal opioid overdose at each stage of the timeline, it can also be used 
to estimate the average length of time between the different stages. 
 
What is the growing risk following first use of medications? How rapidly does that risk increase? When 
does more continuous use become risky and how long does that take? After a nonfatal overdose (NFO), 
what are the risks for a second NFO and how long does that take? Finally, how has the availability of 
illicit fentanyl in the drug supply system changed these timelines? 
 
To fully understand how the transitions operate from one stage of opioid use to the next and how 
individual risk can be reduced, individual demographics, social determinants, medication use and other 
factors should be examined in concert to develop an individualized risk model. That work is beyond the 
scope of this report. The following section will provide an initial glimpse of timeline from opioid naive to 
fatal opioid overdose.
                                                          
21
 Somerville NJ, O’Donnell J, Gladden RM, et al. Characteristics of Fentanyl Overdose — Massachusetts, 2014–2016. MMWR 
Morb Mortal Wkly Rep 2017;66:382–386. DOI: http://dx.doi.org/10.15585/mmwr.mm6614a2 
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Section II.a Risks for Fatal Opioid Overdose 
among the Opioid Naïve  
 
Background: In the 1990s, support was building for greater use of opioids to 
manage pain.22 Throughout the early 2000s, there was a steady increase in 
opioid prescribing for acute and chronic pain.23 24 For many years, this increase 
closely paralleled an increasing opioid-related death rate in Massachusetts and 
elsewhere, but rates for opioid prescribing and opioid related overdose deaths 
have gone in different directions in recent years.25 That fact could be used to 
argue against the importance of examining opioid naïve individuals. However, 
given the long-term statistical relationship between prescribing and overdose 
deaths from the early 2000s, it is important to better understand the rate at 
which this risk increases. 
 
Studies also show that the transition from opioid naïve to opioid tolerant can be 
very brief – as little as one week.26 Despite the short time it takes for the body 
to develop tolerance to opioids, relatively little is known about the short, mid, 
and long-term risks of opioid prescribing to the opioid naïve. The Chapter 55 
data set provides an opportunity to examine the risk for persons with little or no 
exposure to prescription opioids and to track those risks over time. 
 
Basic Methods: A binary operational definition for persons who were opioid 
naïve was developed using Chapter 55 data. All individuals were classified as 
either opioid naïve or not opioid naïve. To be categorized as opioid naïve, the 
individual’s records had to show a period of six months or more without an 
opioid prescription before their first opioid prescription. Patients excluded from 
the group include those who: 
 
 had any advanced cancer (other than non-melanoma skin cancer) 
 had a substance use disorder diagnosis in the six months preceding their 
first opioid prescription, or 
 whose first prescription was for any buprenorphine formulation 
indicated for treatment of substance use disorder 
                                                          
22
 McQuay H. Opioids in pain management. Lancet 1999, 353: 2229-2232. 
23
 Kenan et al. Trends in prescriptions for oxycodone and other commonly used opioids in the 
United States, 2000-2010. Open Med. 2012 Apr 10;6(2):e41-7. Print 2012. 
24
 Okie S. A Flood of Opioids, a Rising Tide of Deaths. N Engl J Med 2010; 363:1981-1985 
25
 Pezalla et al. Secular trends in opioid prescribing in the USA. J Pain Res. 2017; 10: 383–387. 
26
 Accessed at http://professionals.ufhealth.org/files/2011/11/0312-drugs-therapy-bulletin.pdf on 
5/19/2017. 
Data sources: 
  
 Medical claims 
 Hospital, ED, and 
outpatient data 
 Death records 
 Ambulance trips 
 Prescription Drug 
Monitoring Program 
 Substance Abuse 
Treatment 
Current Status: While 
there is consensus that 
long-term and high dose 
prescribing of opioids 
puts patients at 
increasing risk of fatal 
and non-fatal opioid-
related overdose, 
additional evidence is 
needed about the short-, 
mid-, and long-term risks 
of opioid prescribing to 
the opioid naïve. 
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Opioid naïve populations were examined annually between 2011 and 2015. 
They were compared to the general population for rate of fatal opioid overdose. 
 
Key Findings:  
 
 The number of new opioid prescriptions dropped by roughly 50% 
between 2012 and 2015. Over three million individuals received new 
opioid prescriptions during the study period with a death rate of 6.2%. It 
is possible that the high death rate may reflect use of opioids for 
palliative care.  
 The number of first prescriptions for patients classified as opioid naïve 
using the definition above dropped by nearly half between 2012 and 
2015. 
 
 
 
 Opioid naïve patients were tracked for up to 66 months following the 
initial prescription. For those who died of an opioid-related cause, the 
mean length of time from initial prescription to the opioid-related 
overdose death was 36 months.  
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Key Finding: The number 
of initial prescriptions for 
patients classified as 
opioid naïve using the 
definition above dropped 
by nearly half between 
2012 and 2015. 
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 Almost half of all individuals who died of an opioid-related overdose 
during the study period were at one time classified as opioid naïve 
during the study period. 
 
Recommendations for Further Analysis: 
 Examine the risk of this population to determine other factors which 
increase, decrease, or mitigate the risk of fatal opioid overdose.  
 Compare the data for this population to the post-mortem toxicology 
reports to determine if people are dying from prescribed opioid 
medications or if they have made the transition to illegal drugs such as 
heroin. 
 Measure the average length of time between opioid naivety and coding 
of opioid use disorder in administrative data sets. 
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Section II.b Continued Use of Prescription 
Opioids and Risk of Fatal Overdose 
 
Background: Concern about changes in opioid prescribing practices has been 
evident for over a decade.27 Most people who receive an initial prescription for 
opioids after surgery or for pain do not continue to receive opioids after 
completing the initial prescription. 28 However, since most Massachusetts adults 
have filled an opioid prescription between 2011 and 2015,29 any increasing risk 
associated with the continued use of prescription opioids puts hundreds of 
thousands of individuals at some ongoing risk for fatal and nonfatal opioid 
overdose. The analyses presented in this section will be a continuation of the 
work presented in the previous section on the opioid naïve population. The 
same cohorts will be tracked and estimates of fatal overdose risk will be 
calculated for different lengths of time of continued use. 
 
Basic Methods: A cohort who filled an opioid prescription for three months in 
2011 or six months in 2011 or all 12 months in 2011 was tracked from 2011 
through 2015 to see how many of them died from opioid-related overdoses 
each year.  Data from the Prescription Drug Monitoring Program was linked to 
death records for this analysis. The goal was to see how risk of death increased 
through time and as a function of the number of months an individual had a 
prescription for opioids in 2011. 
 
Key Findings:  
 There has been a 47% decrease in the number of opioid naïve 
individuals between 2011 and 2015, and the total number of opioid 
prescriptions dropped 10% from its peak in 2012 to 2015. 
                                                          
27
 Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: 
Concerns and strategies Drug and Alcohol Dependence 81 (2006) 103–107. 
28
 Clarke H, et. al. Rates and risk factors for prolonged opioid use after major surgery: population 
based cohort study. BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1251 (Published 11 
February 2014) Cite this as: BMJ 2014;348:g1251 
29
 In the previous section, it was stated that “Over three million individuals received new opioid 
prescriptions during the study period.” 
Current Status: Since 
many Massachusetts 
adults have filled an 
opioid prescription 
between 2011 and 2015, 
any increasing risk 
associated with 
continued use of 
prescription opioids puts 
hundreds of thousands of 
individuals at some 
increased level of risk for 
fatal and nonfatal opioid-
related overdose. 
Data Sources: 
  
 Death records 
 Prescription Drug 
Monitoring 
Program 
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 1.1 million people who filled opioid prescriptions in 2011 were tracked 
over time.  Of these, over 40,000 persons were prescribed opioids for 
the entire year, over 120,000 had more than six months of prescribed 
opioids, and over 220,000 persons had over three months of prescribed 
opioids. 
 Compared to the general population, those who received three months 
of prescribed opioids in 2011 were four times as likely to die from an 
opioid-related overdose within one year, and 30 times as likely to die of 
an opioid-related overdose within five years. 
 
  
 
 
Recommendations for Further Analysis:  
 A deeper analysis is required to understand the impact of fentanyl on 
the risk timeline for this 2011 cohort. It is possible that the trends seen 
for the persons prescribed opioids in 2011 may be different than in 
years where fentanyl was prevalent and opioid prescribing had dropped 
to some extent. 
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overdose within five 
years. 
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 The analysis should be combined with post-mortem toxicology to 
determine if it is possible to pinpoint with some accuracy the point at 
which individuals transition from legal to illegal opioids. 
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Section II.c Risk of Overdose and Death after a 
Nonfatal Opioid Overdose 
 
Background: Identifying individuals with a non-fatal overdose (NFO) related to 
opioids and determining treatment patterns and use of substance use 
treatment services may provide an opportunity to intervene and improve future 
outcomes. Previous research has shown that mortality among individuals with 
substance use disorders is high, even among those receiving treatment.30 
Additionally, individuals having an NFO from opioids, heroin, or related drugs 
may suffer from substantial morbidity from injuries and illnesses caused by the 
NFO.31 Increased access to opioid agonist treatment has been shown to be 
associated with a decrease in heroin associated deaths.32  
 
Understanding the post-NFO risk can guide government agencies and the health 
care system to deliver more integrated care that reduces the likelihood of 
subsequent fatal opioid overdose. Additionally, treating conditions related to 
opioid use and NFOs may be very expensive for private and government 
insurers,33 so better understanding treatment access and provision may improve 
the evidence available for policy on appropriate treatment access and 
utilization.  
 
Basic Methods: A cohort was constructed of Massachusetts residents ages 11 
years or older who had either an opioid-related fatal overdose or NFO within 
the 2011-2015 period.34 Individuals were identified for this cohort using hospital 
discharge data, data on ambulance responses, and death records. The cohort 
was tracked to determine whether individuals had 1) an overdose (fatal or non-
fatal) at any point, and 2) a repeat overdose after the original NFO. Insurance 
status was determined using the All Payer Claims Database.  
                                                          
30
 Gossop M, Stewart D, Treacy S, Marsden J. A prospective study of mortality among drug 
misusers during a 4-year period after seeking treatment. Addiction. Jan 2002;97(1):39-47. 
31
 Warner-Smith M, Darke S, Day C. Morbidity associated with non-fatal heroin overdose. 
Addiction. Aug 2002;97(8):963-967. 
32
 Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose 
deaths in Baltimore, Maryland, 1995-2009. American journal of public health. May 
2013;103(5):917-922. 
33
 Clark RE, Samnaliev M, McGovern MP. Impact of substance disorders on medical expenditures 
for medicaid beneficiaries with behavioral health disorders. Psychiatric services. Jan 
2009;60(1):35-42. 
34
 Note that individuals in the cohort could enter with either an original fatal overdose or a non-
fatal overdose. For those whose initial overdose was fatal, we observe them as censored in our 
follow-up data. However, the construction of the original overdose cohort in this manner allows 
us to determine overall trends in the insurance status and type of individuals experiencing an 
opioid overdose at any point in the time period.  
Current Status: Previous 
research has shown that 
mortality among 
individuals with 
substance use disorders 
is high, even among 
those receiving 
treatment. 
Data Sources: 
 
 Medical claims 
 Hospital, ED, and 
outpatient data 
 Death records 
 Ambulance trips 
 Post-mortem 
Toxicology 
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For the overdose cohort, we constructed two datasets – one with follow-up 
information for 12 months including the month of the first fatal overdose or 
NFO, and one with follow-up information for 24 months including the month of 
the first overdose. Estimates of the rate of fatal and repeat nonfatal overdoses 
were calculated. 
 
 Key Findings:  
 Of the Massachusetts residents who had a nonfatal overdose (NFO) 
between 2011 and 2015, 94.8% of them were insured for the majority 
of the two-year follow-up period. Of those who were insured, 76.8% 
were enrolled in Medicaid.  
 Of the Massachusetts residents who had a nonfatal overdose (NFO) 
between 2011 and 2015, 6.2% had a fatal opioid-related overdose 
within one year following the initial overdose; 9.3% of the sample had a 
fatal opioid-related overdose within two years following the initial 
nonfatal overdose.35  
 Repeat overdoses were common in the cohort, with 14.9% having one 
or more repeat overdoses during the one-year follow-up period and 
19.1% during the two year follow-up period.  
 
 
 
 For the two year period, being insured (versus uninsured) is associated 
with a 5% increase in the probability of a repeat overdose, controlling 
for demographics and health services utilization. However, being 
insured (versus uninsured) is associated with a 7% reduction in the 
                                                          
35
 This includes individuals who had a fatal overdose as their initial entry into the overdose cohort. 
6.2% 
9.3% 
14.9% 
19.1% 
0%
5%
10%
15%
20%
25%
Initial
Overdose
2 Year
Followup
1 Year
Followup
2 Year
Followup
Fatal Overdoses . Repeat Overdoses
Nearly 1 in 10 Die with in 2 Years After  
an Initial Nonfatal Overdose 
Key Finding: 6.2% of the 
sample had a fatal 
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Key Finding: Repeat 
overdoses were common 
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probability of having a fatal opioid-related overdose at any point during 
the period (including the initial overdose). 
 
Recommendations for Further Analysis:  
 More advanced statistical modeling should be conducted to control 
for length of follow-up, comorbidities that impact medical care 
utilization, and differences in socioeconomic status.  
 Examining associations between insurance status and type with 
opioid prescriptions and prescription use following an NFO is an 
important area for further study. 
 There should be further examination of treatment provided to high-
risk individuals by insurers in order to ensure that they have 
appropriate access to evidence-based treatment. 
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Section II.d Estimating the Impact of Fentanyl 
on Fatal Opioid-Related Overdoses 
 
Background: Fentanyl is a synthetic opioid. It is a schedule II prescription 
drug,36 and it is typically used to treat patients with severe pain or to manage 
pain after surgery.37 While similar to morphine, fentanyl is estimated to be 50 to 
100 times more potent.38 39 However, fentanyl is also increasingly manufactured 
illicitly and distributed for non-medical purposes often mixed with heroin or 
substituted for heroin without the users’ knowledge.   
 
Nationally, two in five heroin-related deaths have involved fentanyl and the rate 
appears to be higher in Massachusetts.40 41 Adding to the public health concern 
is the fact that new synthetic opioids are now being found in New England. A 
recent warning about carfentanil is evidence of the evolving risk.42 In some 
cases, these new Illicit synthetics are many times as potent as fentanyl which is 
almost always illicit as well. 
 
When illicit fentanyl became common in the drug supply in Massachusetts, the 
death rates went up sharply. While evidence is emerging that fentanyl is a 
strong contributor to the sharp increase in opioid-related deaths in 
Massachusetts.43 this analysis will attempt to shed some additional light on that 
question. 
 
 
                                                          
36
 Controlled Substances Act. Vol 21 CFR 1308.12. 
http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_12.htm. 
37
 Nelson L, Schwaner R. Transdermal fentanyl: Pharmacology and toxicology. J Med Toxicol. 
2009;5(4):230-241. doi:10.1007/BF03178274. 
38
 Volpe DA, Tobin GAM, Mellon RD, et al. Uniform assessment and ranking of opioid Mu receptor 
binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59(3):385-390. 
doi:10.1016/j.yrtph.2010.12.007. 
39
 Higashikawa Y, Suzuki S. Studies on 1-(2-phenethyl)-4-(N-propionylanilino) piperidine (fentanyl) 
and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-
substituted fentanyls and other analogues. Forensic Toxicol. 2008;26(1):1-5. doi:10.1007/s11419-
007-0039-1. 
40
 Gladden RM, Martinez P, Seth P. Fentanyl law enforcement submissions and increases in 
synthetic opioid-involved overdose deaths — 27 states, 2013–2014. MMWR Morb Mortal Wkly 
Rep 2016; 65: 837-43 
41
 Accessed at http://www.mass.gov/eohhs/docs/dph/stop-addiction/current-statistics/data-
brief-overdose-deaths-may-2017.pdf on 5/19/2017. 
42
 Ohannessian, Dana “Re: Situational Awareness Alert for the Drug Carfentanil - Message from 
DPH.” Received 5/15/2017 via email. 
43
 Somerville NJ, O’Donnell J, Gladden RM, et al. Characteristics of Fentanyl Overdose — 
Massachusetts, 2014–2016. MMWR Morb Mortal Wkly Rep 2017;66:382–386. DOI: 
http://dx.doi.org/10.15585/mmwr.mm6614a2. 
Current Status: Nationally, 
two in five heroin-related 
deaths have involved 
fentanyl and the rate 
appears to be higher in 
Massachusetts. 
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Basic Methods: Two models were developed to estimate the impact of fentanyl 
on opioid related deaths in Massachusetts. Model 1 used the annual counts of 
opioid-related deaths between 2000 and 2011 to project annual opioid-related 
deaths for the period from 2011 through 2015. Fentanyl was first noticed in 
Massachusetts deaths beginning around 2011. Actual deaths were compared to 
the expected deaths from the projection model to yield additional deaths that 
may be attributable to fentanyl.  
 
Model 2 also used the individual death records but supplemented this 
information with data from post-mortem toxicology reports as well as basic 
demographics and the individual’s history of opioid use disorder (OUD) including 
medication assisted and other OUD treatments. The model was designed to 
determine the unique contribution that fentanyl has played in the increased 
death rate in Massachusetts.  
 
Key Findings:  
 According to the New England High Intensity Drug Trafficking Area (NE-
HIDTA) group, seizures of pure fentanyl increased sharply between 2011 
and 2015. While seizures of heroin and other opioids doubled in this 
time, fentanyl seizures barely registered in 2011 and increased 70-fold 
between 2014 and 2015.  
 
 Oxycodone is the most commonly prescribed opioid. One in five persons 
dying of an opioid overdose had an active oxycodone prescription at the 
time of death. Less than 2% had an active prescription for fentanyl, a 
number that barely changed over the course of a year. This indicates 
that almost all fentanyl involved in deaths is illicitly obtained. 
 The fentanyl predictive model used trended death data from 2000 
through 2010 to estimate likely deaths in 2011 through 2015. This is the 
dashed line in the figure below. Based on this model, the number of 
additional deaths since 2010 due to fentanyl exceeds 2,000. 
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Key Finding: A simple 
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Data Sources: 
 
 Medical claims  
 Hospital, ED, and 
outpatient data 
 Death records 
 Ambulance trips 
 Post-mortem 
Toxicology 
 Substance Abuse 
Treatment 
Key Finding: While 
seizures of heroin and 
other opioids doubled in 
this time, fentanyl seizures 
barely registered in 2011 
and increased 70-fold 
between 2014 and 2015. 
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Recommendations for Further Analysis: 
 While the increasing levels of fentanyl in the illicit drug supply roughly 
parallel the temporal increase in deaths, a deeper analysis looking at 
each individual’s history of opioid use disorder, previous nonfatal 
overdoses, and mental and physical health co-morbidities is required to 
better understand the impact of fentanyl 
 A geographic time series analysis should be conducted to show the 
spread of fentanyl and its relation to fatal and nonfatal overdose locally. 
If possible, algorithms should be developed to project where hot spots 
may occur in the future. 
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Section III. Identifying At-Risk Populations 
The Chapter 55 data enables the state to simultaneously examine many different groups who may be at 
risk for fatal and non-fatal opioid overdose. This work marks the first population-specific examination of 
opioid related overdose risk for several of the populations characterized in this report.  
 
The strength of the Chapter 55 data comes from the breadth of information gathered together in a 
single place. For example, data on homelessness is limited or not well validated in virtually all data sets. 
However, evidence of homelessness can be found in 12 different Chapter 55 data tables. Pulling 
together these data enables analysts to fill in the gaps in individual histories or even to model missing 
data. This approach has been used to provide a more complete picture of the homeless population in 
the state. The same is true for veterans, those with mental health co-morbidities, young adults, those 
leaving Massachusetts jails and prisons after serving a sentence, mothers with opioid use disorder, and 
individuals served by a number of other government agencies. 
 
The core information presented in each subsection will provide estimates of the risk of fatal and 
nonfatal overdose for each of the populations studied. In addition, the overlap in these populations will 
be presented. This is of particular interest for persons receiving service or aid from a specific 
government agency. Knowing the likelihood that an individual is also connected to another agency may 
offer opportunities to collaborate across government to address the opioid problem. 
 
The subpopulations examined were: 
 
 Massachusetts Veterans served by VA Pharmacies and the Department of Veterans' Services 
 Individuals experiencing an episode of homelessness or housing instability 
 Individuals with Serious Mental Illness (SMI) 
 Young Adults (ages 18-25) 
 Individuals Recently Released from Incarceration in Prisons and Jails 
 Mothers with Opioid Use Disorder 
 Residents of Massachusetts Communities and Regions 
  36 
Section III.a Massachusetts Veterans Using the 
VA Pharmacies and DVS Services 
 
Background: Veterans comprise 5% of the Massachusetts population – more 
than 355,000 persons. A recent survey of Massachusetts veterans indicates that 
they reported problems with binge drinking, symptoms of depression and post-
traumatic stress disorder along with financial, housing, and educational needs,44 
making this group an at-risk population for opioid use disorder. 
 
While a Chapter 55 analysis of the broader relationship between Veterans’ 
status and fatal and nonfatal opioid overdose will be examined at a later date, 
the population of interest here are Veterans who receive services and 
entitlements from the Department of Veterans’ Services (DVS) along with those 
who dually utilize the Federal VA pharmacy for prescriptions, including opiate 
prescriptions. 
 
Basic Methods: DVS provided a complete list of persons receiving financial 
support with DVS funds. Fewer than 10% of the total Veteran population in the 
state received benefits from DVS between 2011 and 2015. In order to expand 
the population to other Veterans, an operational definition of “Veteran” status 
was developed. To be counted as a “Veteran” in the Chapter 55 data set, an 
individual had to meet ANY of the following criteria: 
 
 At least one record for housing, medical or other benefits in the DVS 
data between 1/1/2011 and 12/31/2015 AND was at 18 years old or 
more. 
 At least one prescription filled at a VA pharmacy between 1/1/2013 – 
12/31/2015 (the period for which data were available). 
 At least one prescription in the PMP data between 1/1/2011 and 
12/31/2015 where the type of payment was identified as ‘Military 
Installations and VA.’ 
 A record of death in which the occupation was classified as ‘military.’ 
 
This definition identified 98,433 individuals. The Veterans identified using the 
definition above were cross-tabulated with the other at-risk groups reported on 
                                                          
44
 Supporting Those Who Served in Massachusetts Needs, Well-Being, and Available Resources for 
Veterans by Carrie M. Farmer, Terri Tanielian, Shira H. Fischer, Erin L. Duffy, Stephanie Dellva, 
Emily Butcher, Kristine Brown, Emily Hoch Copyright: RAND Corporation Availability: Web-Only, 
DOI: 10.7249/RB9945 Document Number: RB-9945-KLAFF 
Current Status: 
Massachusetts veterans 
report problems with binge 
drinking, symptoms of 
depression and 
posttraumatic stress 
disorder along with 
financial, housing, and 
educational needs. Little is 
known about the specific 
risk of fatal and nonfatal 
opioid overdose among 
Veterans. 
Data Sources: 
  
 Medical claims 
 Hospital, ED, and 
outpatient data 
 Death records 
 Ambulance trips 
 Post-mortem 
Toxicology 
 Dept of Veterans’ 
Services 
  37 
in this section. Finally, estimates of the rates for fatal overdoses were calculated 
for this group of Veterans.  
 
Key Findings:  
 The average veteran identified was 54 years old, but the age 
distribution indicated that there were two distinct groups of veterans – 
one with an average age of 32 and the other with an average age of 67. 
More than half of the Massachusetts veterans identified were men. 
 Unlike most at-risk populations, the Massachusetts veterans examined 
here had relatively little overlap with other at-risk groups. One quarter 
were insured through MassHealth. 
 
 
 
 The percentage of identified veterans who had a fatal opioid overdose 
was three times the state average. This was an unadjusted estimate, 
which did not control for Veteran specific characteristics such as age, 
physical and mental health co-morbidities, etc. Generation of an 
adjusted estimate is planned as part of further analyses. 
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Recommendations for Further Analysis: 
 Examine “dual use” in this Veteran sample for opioid prescriptions (i.e., 
how many Veterans are getting their opioid prescriptions from both VA 
and non-VA pharmacies as compared to only VA pharmacies). Further, 
examine whether these dual users are at an increased risk of opioid use 
disorder, non-fatal opioid overdose and fatal opioid overdose.  
 Estimate prevalence of opioid use disorder, non-fatal opioid overdose, 
and fatal opioid overdoes in sub-groups of at-risk Veterans (i.e., 
homeless, depressed, and those with PTSD).  
 Examine effect of the VA’s Opioid Safety Initiative launched in 2013 on 
the rates of opioid use disorder and opioid related deaths in Veterans in 
Massachusetts.  
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Section III.b Individuals Experiencing 
Homelessness  
 
Background: Homelessness has been a persistent societal problem in 
Massachusetts and nationwide for decades.45 Despite the length of time 
policymakers have recognized the problem, accurate and complete data is 
difficult to obtain primarily because data systems are not well organized to track 
individuals experiencing homelessness.  Some estimates, however, do exist.  A 
2016 point-in-time count in Massachusetts found that roughly 19,600 persons 
were experiencing homelessness on a given night—of whom about two thirds 
were persons in families and the remaining one third were single homeless 
adults.46 Point-in-time counts, however, do not adequately capture the issue of 
housing instability or episodic homelessness since an individual’s or family’s risk 
of homelessness may be transient. 
 
With respect to risk of fatal and nonfatal opioid-related overdose, a 2003-2008 
study of homeless adults in Boston found that drug overdose was the leading 
cause of death for this population, occurring at rates 16-24 times higher than in 
the general population. Opioids were a factor in over 80% of these deaths.47 In 
light of dramatic recent increases in opioid-related fatalities nationally, a more 
comprehensive and updated assessment of opioid overdose deaths among 
individuals experiencing homelessness in Massachusetts is warranted. 
  
Basic Methods: Government agencies routinely collect vast amounts of 
administrative data to track events and transactions. These data include 
information about homelessness and housing instability in various forms, and 
while extensive, these data are limited in important ways. One commonly cited 
limitation of administrative data is the likelihood that some information 
recorded is incomplete.48 For example, data on emergency shelter utilization 
represent one of the most commonly used sources of administrative data to 
identify homelessness but do not identify homeless persons who do not use the 
emergency shelter system. Other administrative data sources such as medical 
records, data collected about ambulance trips, and death records include 
indicators of homelessness and housing instability, but not all episodes of 
homelessness are likely to be captured and diagnosis codes indicating 
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 Lee, B. A., Tyler, K. A., & Wright, J. D. (2010). The new homelessness revisited. Annual review of 
sociology, 36, 501-521.  
46
  https://www.hudexchange.info/resource/5178/2016-ahar-part-1-pit-estimates-of-
homelessness/  
47
 January 14, 2013. doi:10.1001/jamainternmed.2013.1604 
48
 Accessed at https://archive.ahrq.gov/data/safetynet/billings.htm on 5/19/2017. 
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homelessness may not be listed during a medical encounter even for those who 
are experiencing an episode of homeless. For this study, mathematical modeling 
was therefore used to project the incomplete parts of data sets in order to yield 
a reliable prevalence estimate for individuals experiencing homelessness in 
Massachusetts.49 
 
Analysts used 5,050,639 records that were linked at the individual level across 
14 administrative data sets. To be included, individuals had to have data in at 
least one data set in addition to the All Payer Claims Database. 50  
 
The records were randomly split into two portions – a training data set with 75% 
of the records and a test data set with the remaining 25%. Homelessness was 
specifically coded in the All Payer Claims Database, CaseMix (hospital, ED and 
outpatient data), ambulance trip, Prescription Drug Monitoring Program, and 
Department of Mental Health data, and an indicator in any of these datasets 
was categorized as a coded instance of homelessness.51 Predictive models using 
logistic regression were developed on the training data set to estimate the 
likelihood of coded homelessness using more than 100 predictors. 
 
The resulting model was validated on the test data set on the coded 
homelessness measure described above and also other related variables. Since 
the validation demonstrated that the estimated homelessness values were 
predictive of expected outcomes, a final homelessness measure was created 
using actual coded values where available and predicted probabilities where no 
code existed. These values were examined with respect to fatal and nonfatal 
opioid overdose to determine the risk for this vulnerable population. 
 
Key Findings:  
 By linking data sets together and modeling patterns that could be 
related to homelessness, it is estimated that 1 in 25 adults (3.7%) was 
likely to have been homeless at some point between 2011 and 2015. 
                                                          
49
 Our focus in this work is primarily on the single adult homeless population with a future analysis 
to focus more specifically on the discrete population of persons in families experiencing 
homelessness. This distinction is warranted in light of evidence of differences in the 
characteristics of the single adult and family homeless along several dimensions. 
50
 Since the APCD forms the spine of the Chapter 55 data system, all individuals have at least some 
data in the APCD. 
51
 Records on the use of the Emergency Assistance (EA) family shelter system were available from 
the Department of Housing and Community Development (DHCD), but were not included as an 
indicator of homelessness in the current analysis, as the intent was to identify the single adult 
homeless population as far as was possible with the available data. 
Key Finding: When relying 
exclusively on homeless-
specific administrative 
codes, only 1% of the 
population was homeless 
between 2011 and 2015. 
However, by linking data 
sets together and 
modeling patterns that 
could be related to 
homelessness, it was 
estimated that 1 in 25 
adults (3.7%) was likely to 
have been homeless at 
some point between 2011 
and 2015. 
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 At least three in eight adults who experienced homelessness between 
2011 and 2015 have a coded diagnosis of a serious mental illness.52 
  
 
 The opioid overdose death rate is between 16 and 30 times higher for 
the homeless individuals compared to the rest of the adult population.53 
 
  
 
Recommendations for Further Analysis: 
 Build on this initial analysis of the relationship between homelessness 
and opioid overdose to assess other questions of interest related to 
homelessness housing status. Potential areas for inquiry include: 
examining whether homeless status modifies (either positively or 
negatively) the effectiveness of naloxone; assessing whether persons 
experiencing homelessness are more likely to experience fatal 
                                                          
52
 Coded in one or more of the administrative data sets. 
53
 The rate is 16 times higher for coded administrative data and 30 times higher for the modeled 
results. 
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overdoses in which fentanyl is present; examine health care utilization 
patterns among persons experiencing homelessness to identify 
potential intervention points.  
 Since the risk of opioid related death is significant for individuals 
experiencing homelessness, we should also examine fatal and non-fatal 
opioid overdose specifically among families who use the DHCD 
Emergency Assistance family shelter system. 
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Section III.c Individuals with Serious Mental 
Illness (SMI) 
 
Background: Persons with substance use disorder (SUD) have been found to be 
twice as likely to have mood or anxiety disorders.54 However, among the 
criminal justice involved population, almost half have both a diagnosis of a 
serious mental health condition and substance use disorder.55 In January 2017, 
the Substance Abuse and Mental health Services Administration (SAMHSA) 
estimated that 1.5 million adults with serious mental illnesses (SMI) had 
misused opioids in the previous year.56 SAMHSA defined SMI as “a diagnosable 
mental, behavioral or emotional disorder (excluding developmental and 
substance use disorders) of sufficient duration to cause serious functional 
impairment in an individual’s major life activities (going to work, school, 
interacting with family, etc.).” The specific diagnostic categories included were 
mood disorders, schizophrenia, and other psychotic disorders. While the rate of 
opioid misuse is higher in the SMI population, the impact on fatal and nonfatal 
overdoses is not known.  The Chapter 55 data system can shed much light on 
these relationships. 
 
Basic Methods: MassHealth prepared data that flagged persons with SMI using 
ICD 9 and ICD 10 diagnosis codes found in any medical claims administered by 
MassHealth. This flag was only available for MassHealth Clients and was based 
on the MassHealth definition of SMI. Other diagnosis groups were examined 
using the Case Mix hospital, ED, and outpatient data sets.  These included 
Stress/Anxiety, Depression, Early Onset/ADHD, and Neuro-Cognitive diagnoses. 
Comparisons between the SMI group using MassHealth data and the hospital-
based diagnoses using Case Mix should be done with caution.  
 
The risk of fatal and nonfatal overdose may be overestimated if based on the 
opioid-related risk for the populations identified from hospital events, since 
hospital-related events may capture persons with more serious conditions than 
those identified through medical claims. All five groups examined with respect 
to fatal opioid overdose and comparisons were made to the rest of the adult 
population in Massachusetts. Additional comparisons were made between SMI 
and other at-risk populations. 
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 Accessed at https://www.drugabuse/gov/publications/drgfacts/comorbidity-addiction-other-
mental-disorder on 5/19/2017. 
55
 Accessed at https://www.drugabuse.gov/sites/default/files/rrcomorbidity.pdf on 5/19/2017. 
56
 Accessed at https://www.samhsa.gov/newsroom/press-announcements/201701241230 on 
5/19/2017. 
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Key Findings:  
 Roughly one in four persons ages 11 and older in the MassHealth 
population was identified as having a serious mental illness. Of these 
individuals, nearly two in five have been homeless for some period of 
time between 2011 and 2015 while one in four has been served by the 
Department of Transitional Assistance. 
 
 
  57 
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 Since only MassHealth data was used to identify SMI, all persons with SMI in this study were 
insured by MassHealth.  
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 Of individuals diagnosed with SMI in the MassHealth population, the 
opioid-related overdose death rate is more than six times the state 
average. 
 In the Chapter 55 data set, through hospital records, one in six persons 
was identified having a stress or anxiety diagnosis, one in 10 persons in 
was identified as having a depression diagnosis, and one in 40 persons 
was identified as having a neuro-cognitive diagnosis. 
 The opioid-related overdose death rate was roughly two times higher 
than the state average for those identified as having a stress or anxiety 
diagnosis. 
 The opioid-related overdose death rate was roughly three times the 
state average for those identified as having a depression diagnosis. 
 The opioid-related overdose death rate was roughly seven times higher 
than the state average for those identified as having a neuro-cognitive 
diagnosis. 
 
  
 
 
Recommendations for Further Analysis: 
 Examine all deaths that might be considered premature in order to 
better understand whether a larger number of cases involving persons 
with a serious mental illness might actually be intentional deaths (i.e., 
suicides). 
 Examine nonfatal overdoses to see if the proportion is related to greater 
degrees of isolation. 
 
  
30.3 34.1 
37.0 
86.1* 95.6 
12.8 
 -
 20
 40
 60
 80
 100
 120
Anxiety Depression ADHD SMI Neuro Cog MA
D
e
at
h
s 
P
e
r 
1
0
0
,0
0
0
 
Very High Rates of Fatal Opioid Overdoses for Persons 
with Some Mental Health Diagnoses 
*Among MassHealth members only 
Key Finding: The risk of fatal 
opioid-related overdose is 
six times higher for persons 
diagnosed with a serious 
mental illness (SMI) and 
three times higher for those 
diagnosed with depression. 
  46 
Section III.d Young Adults (18 – 25 years old) 
 
Background: Eight percent of the state’s population (538,000 persons) are 18-
25 years old (i.e., “young adults”).58 Nationally, young adults have a higher 
prevalence of prescription drug misuse than any other group with 5.9 percent 
reporting nonmedical use in the past month.59 Between 2002-2004 and 2011-
2013, heroin use in young adults increased 108% and fatal overdoses increased 
86%.60 In 2014, young adults had the highest prevalence of past-year heroin use 
(0.8%) and prescription drug misuse (12.0%) compared to other age groups. 
When examining recent illicit drug use, young adults are almost three times as 
likely to report past year illicit drug dependence and misuse as the general 
population.61 Young adults who use substances are also three times more likely 
to be HIV positive and twice as likely to have past year history of civil 
commitment (Section 35) to treatment. 
 
Since young adults may respond to engagement and treatment differently than 
older adults, further examination into developmental differences in this age 
group and the need to take a tailored approach to understanding their specific 
risk factors and treatment needs are critical.  
 
Basic Methods: Age is a core demographic variable in the All Payer Claims 
Database (APCD) and thus young adults are represented in the Chapter 55 data 
as fully as they are represented in the APCD. The Center for Health Information 
and Analysis (CHIA) estimates that annual representation of Massachusetts 
residents in the APCD exceeds 97%. Since the vast majority population was 
represented, no mathematical modeling or weighting was required. 
 
Key Findings:  
 In general, young adults did not overlap with other at-risk groups. 
Approximately one-third were insured by MassHealth. One in 20 had 
been homeless and one in 20 had a diagnosis for a serious mental 
illness. 
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 Accessed at http://censusviewer.com/state/MA/2010 on 5/19/2017. 
59 Accessed at https://www.drugabuse.gov/publications/research-reports/prescription-
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60 Rudd R, Aleshire N, Zibbell J, Gladden M. Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R. 
Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal 
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 Jones CM, Logan J, Gladden RM, Bohm MK. Vital Signs: Demographic and Substance Use Trends 
Among Heroin Users - United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 
2015;64(26):719-725 
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 Of all individuals experiencing a nonfatal opioid-related overdose 
between 2012 and 2014, 19% were young adults (they made up 8% of 
the overall population). 
 Young adults were 189% more likely to be HIV positive and 79% more 
like to have a history of civil commitment to treatment within the past 
year than older adults. 
 
  
 While the opioid-related overdose death rate is lower for young adults, 
it is a critical time to intervene since death rates for older adults 
increases dramatically. Among individuals who had a nonfatal overdose, 
there were no differences between young adults and older adults in 
gender, recurrent overdose, or subsequent fatal overdose. 
 
Recommendations for Further Analysis: 
 Catalog the specific services that are already in place for young adults in 
order to determine whether more (and how many more) should be 
allocated. 
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 Describe the geographic distribution of nonfatal overdoses among 
young adults. 
 Determine whether there are gender-specific risk factors for young 
adults who experience a nonfatal overdose that have implications for 
public health interventions or policy. 
 Examine the factors associated with engaging in medication treatment 
for young adults (buprenorphine, methadone, or naltrexone) after an 
overdose. 
 Evaluate the rates of nonfatal opioid-related overdose in this 
population.  
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Section III.e Persons Released from 
Incarceration in Prisons and Jails  
 
Background: At the end of 2011, 7 million Americans were under correctional 
supervision, including 2.2 million held in jail or prison62. Of those incarcerated, 
nearly two-thirds (1.5 million) have substance use disorders, including up to 
one-quarter with opioid use disorder63,64,65. It has been estimated that one-third 
of heroin users pass through correctional facilities annually66. Few inmates with 
opioid use disorder receive addiction treatment during incarceration, and rates 
of relapse and opioid overdose-related deaths (109 deaths per 100,000 person 
years, or 15 percent of all deaths among former inmates) are tragically high 
following release67 68 69 70. 
 
Data from Massachusetts prisons and jails were used in this report. The 
Massachusetts Department of Corrections (DOC) manages all seventeen71 state 
correctional facilities or prisons. The 15 county jails72 or Houses of Correction 
(HOC) are managed by the county sheriffs. According to the DOC, the MA prison 
population continued to decline for the fourth year, dropping 15% after a peak 
of 11,723 inmates on January 1, 2012 to 10,014 inmates on January 1, 2016. The 
number of criminal releases increased averaging 277 per month (3,329 total) 
during 2015.73 The DOC has acknowledged the drug problem within the prison 
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 Massachusetts Department of Correction, 2015 Annual Report 
Current Status: the 2016 
Chapter 55 opioid report 
found an approximately 50 
times higher opioid 
overdose death rate in 
formerly incarcerated 
people than among non-
incarcerated 
Massachusetts residents. 
Individuals incarcerated in 
Massachusetts jails were 
not examined previously. 
 
Data sources: 
  
 Medical claims 
 Hospital, ED, and 
outpatient data 
 Death records 
 Ambulance trips 
 Post-mortem 
Toxicology 
 Dept of Correction 
 Houses of Correction 
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population.74 Indeed, the 2016 Chapter 55 opioid report found an approximately 
50 times higher opioid overdose death rate in formerly incarcerated people 
compared with non-incarcerated Massachusetts residents.75 
 
Basic Methods: The DOC and the county-based HOC data provided a complete 
listing of persons “released to the street” for the Chapter 55 study. DOC records 
covered the period 1/1/2011 through 12/31/2015. HOC records covered a 
slightly shorter period – 7/1/2011 through 12/31/2015. Since nearly the entire 
population was represented, it was decided that no mathematical modeling 
would be required to estimate the likelihood that a person had been released 
from a prison or jail. The linkage rate of DOC and HOC records to the APCD spine 
were 89.7% and 81.8% respectively.76  
 
Key Findings:  
 During the time period, there were 30,056 recently released inmates 
from the Department of Correction (DOC) and 29,068 from the House of 
Correction (HOC) for a total of 53,956 former inmates. Twenty-five 
percent of Massachusetts prison inmates from DOC received treatment 
during their incarceration. 
 The opioid overdose death rate is 120 times higher for those recently 
released from incarceration compared to the rest of the adult 
population. 
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data for FY2012 quarter 2, and Worcester County did not provide offender date of birth for 
CY2012 through CY2013 Q4, so their information is excluded for this analysis. 
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Opioid Death Rate 120 Times Higher 
for Individuals with Histories of Incarceration 
Key Finding: The majority of 
individuals with history of 
incarceration have 
insurance through 
MassHealth; 42% of former 
inmates were considered 
homeless and 54% were 
considered as having an 
opioid use disorder. 
 
Key Finding: Compared to 
the rest of the adult 
population, the opioid-
related overdose death rate 
is 120 times higher for 
persons released from 
prisons and jails. 
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 About three in five former inmates were considered homeless (coded 
plus estimated), over half were considered as having an opioid use 
disorder. Less than 2% were also among the veterans examined in this 
study. 
  
 
 Opioid-related deaths among persons recently released from 
incarceration have increased over 12-fold between 2011 and 2015. Two 
in five deaths were opioid-related corresponding to one of every six 
opioid-related overdoses deaths in the state.  
 In 2015, nearly 50% of all deaths among those released from 
incarceration were opioid-related.  
 
 
 
 Inmates who died from opioid-related overdoses were significantly 
younger than those inmates that died from other causes (36.2 vs. 46.5 
years).  
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 For individuals who died, the mean time from release to death was 19 
months, ranging from dying within the same month as release (or in 
prison) to 58 months later. The first month after release proved to be a 
critical time period for former inmates. Opioid-related overdose death 
rates were significantly higher than for subsequent months.77 
 
 
 Former inmates who died from opioid-related overdoses were on 
average younger, more likely to be male, more likely to be White non-
Hispanic, more likely to have a high school education or less, less likely 
to be married at or around the time of death, less likely to be in a 
management or professional occupation, more likely to be in a service 
and in farming/fishing/construction profession, and more likely to be 
recorded as a veteran on death certificates compared with those who 
died from all other reportable causes. 
 
 
Recommendations for Further Analysis:  
 Examining the impact of treatment on fatal and nonfatal overdose to 
determine if specific models are more effective with individuals who 
have been released from incarceration. 
 More advanced statistical modeling should be conducted to control for 
length of prison time, comorbidities that impact medical care utilization, 
and other differences in socioeconomic status. 
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Section III.f Mothers with Opioid Use Disorder  
 
Background: Mothers with opioid use disorder (OUD) are a population of 
particular concern, since perinatal opioid use is not only associated with adverse 
health outcomes for the mother, but also with adverse health outcomes for her 
offspring across the life course. While 2013 estimates of current illicit drug use 
among persons aged 12 and older are higher for men than for women (11.5% 
vs.7.3%), research indicates women progress more rapidly to problem use.78 79 80  
 
The proportion of pregnancy-associated deaths (deaths during or within one 
year of the end of pregnancy) in Massachusetts related to substance use 
increased from 14% in 2011 to 41% in 2014.81 Opioids were the most common 
substance indicated in these deaths. However, little is known about nonfatal 
opioid-related overdoses during pregnancy and following delivery. Because 
screenings of women in primary or prenatal care is not universal, opportunities 
are likely missed to identify women in need of OUD evaluation and treatment 
referral. The breadth of the Chapter 55 data set provides an opportunity to 
better understand whether pregnant women and new mothers with OUD are at 
greater or lesser risk of fatal and nonfatal overdose compared with new 
mothers who do not have an OUD and understand the timing of overdose 
events during the prenatal and postpartum periods. By linking the data of the 
mother and child, the Chapter 55 data set allows close tracking of the impacts 
on the substance-exposed dyad and estimation of future risks. 
 
Basic Methods: A cohort of women who delivered a live birth in Massachusetts 
between 2011—2015 was identified by linking birth certificate records to 
maternal records in the All Payer Claims Database (APCD). Infant diagnosis 
codes for neonatal abstinence syndrome (NAS) documented in APCD and 
CaseMix were also linked to mothers via birth certificate records. Fatal and 
nonfatal opioid overdose events were identified using CaseMix hospital records, 
MATRIS ambulance records, and death certificates. Women were classified as 
having evidence of OUD if any of the following were documented during the 5 
year time period: 
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 Massachusetts Department of Public Health, unpublished data. 
Current Status: Pregnancy-
associated deaths with an 
indication of substance use 
increased from 14% in 2011 
to 41% in 2014. Little is 
known about the risk of 
nonfatal opioid-related 
overdose during pregnancy 
and following delivery. 
Data sources: 
  
 Medical claims 
 Hospital, ED, and 
outpatient data 
 Death records 
 Birth records 
 Ambulance trips 
 Post-mortem 
Toxicology 
 Substance use 
treatment records 
 Prescription records 
  
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 A fatal or nonfatal opioid overdose 
 A diagnosis code related to OUD 
 A claim for methadone or prescription for buprenorphine  
 Record of opioid-related enrollment/treatment in the Bureau of 
Substance Abuse Services (BSAS) database 
 Record of opioid-related treatment while incarcerated    
Finally, data from APCD, Case Mix, birth certificate records, and BSAS were used 
to describe maternal socio-demographic and substance use characteristics 
 
Key Findings:  
 A majority of mothers with OUD had interaction with the Department of 
Transitional Assistance, were insured by MassHealth, and had evidence 
of serious mental illness. One in six had a history of incarceration in 
Massachusetts prisons and jails. 
 
 
 
 Compared to mothers without evidence of OUD or overdose, mothers 
with a fatal or nonfatal overdose and mothers with OUD were 
significantly more likely to be less than 30 years old, White non-Hispanic 
race, born in the United States, unmarried, without paid employment, 
less educated, receive their prenatal care at a hospital clinic, and have 
public insurance. 
 Mothers with OUD had a significantly higher co-occurrence of mental 
health diagnoses. 
o 82% of mothers with an overdose during pregnancy or the first 
year postpartum had a diagnosis of depression during the study 
period compared with 63% of mothers with OUD and 18% of 
mothers without evidence of OUD. 
0% 20% 40% 60% 80% 100%
Insured by MassHealth
Dept Transitional Assistance*
History of Incarceration
Young Adults
Select Veterans (defined above)
Serious Mental Illness
Homeless
Mothers with OUD Had High Rates of Homelessness and 
Serious Mental Illness 
% as a total of the population of mothers with OUD 
* Individuals receiving 
   benefits through DTA. 
Key Finding: Mothers with 
OUD had a significantly 
higher co-occurrence of 
mental health diagnoses. 
82% of mothers with an 
overdose during pregnancy 
or the first year postpartum 
had a diagnosis of 
depression compared with 
63% of mothers with OUD 
and 18.0% of mothers 
without evidence of OUD. 
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o 79% of mothers with an overdose during pregnancy or the first 
year postpartum had a diagnosis of anxiety during the study 
period compared with 62% of mothers with OUD and 18% of 
mothers without evidence of OUD. 
 More than a third (38.3%) of deaths among women delivering a live 
birth between 2011 and 2015 were fatal opioid-related overdoses, 
compared to a fifth (19.9%) among women who did not deliver a live 
birth. 
 The five-year opioid-related overdose death rate of mothers with 
evidence of OUD was 321 times higher than the rate among mothers 
without evidence of OUD and the opioid-related overdose death rate 
among mothers delivering an infant with NAS was 27 times higher than 
the rate for all other mothers. 
 
 
 
 Among women with OUD, women who delivered a live birth between 
2011-2015 were 2.1 times less likely to have a fatal overdose compared 
to women who did not deliver a live birth 
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Opioid Death Rate More than 300 Times Higher 
for Mothers with OUD 
Key Finding: The five-year 
opioid-related overdose 
death rate of mothers with 
evidence of opioid use 
disorder was 321 times 
higher than the rate among 
mothers without evidence 
of opioid use disorder. 
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 Rates of opioid-related overdose decrease during pregnancy and are 
lowest during the second and third trimesters, but significantly increase 
in the postpartum period, with the highest rates six months—one year 
after delivery. 
 
Recommendations for Further Analysis: 
 Assess the impact of treatment engagement and retention on maternal 
overdose during the postpartum period. 
 Determine factors that may predict or protect against overdose among 
mothers in the first year postpartum. 
 Evaluate infant outcomes for women who have nonfatal overdose 
events during pregnancy. 
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Key Finding: The opioid-
related overdose rate 
increases almost four-fold 
between the third trimester 
of pregnancy and the first 
six weeks postpartum. They 
are highest six to 12 months 
post-partum. 
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Section III.g Estimating Opioid Burden for All 
Massachusetts Communities  
 
Background: The scope of the data assembled for the Chapter 55 project has 
enabled the Department of Public Health to examine trends in the data for small 
communities, which is a process that has not previously been possible. Standard 
statistics, based on very limited data, do not lend themselves to making clear 
statements about the burden of specific health conditions when community 
populations are small. However, by linking the Chapter 55 data at the 
community level, it is possible to gain insight into the opioid burden for all 
Massachusetts communities.  
 
Basic Methods: A four-step process was used to estimate overall opioid burden 
for all towns in Massachusetts. An assumption was made that the overall 
burden of the opioid crisis at a community level could best be measured using 
multiple data points that captured different aspects of the crisis. While some 
measures might be higher in one town and lower in another, considering 
multiple measures across time would make the results more reliable.  The 
graphic below depicts the basic approach of combining years, using reliable 
data, adjusting the population for very small towns, and using multiple data 
sources to make all estimates more accurate.  
 
Step 1 (Combine Years): Averaging across years or computing rates for 
multiple years tends to produce more reliable estimates.82 Because some 
data elements were available for all years, only data from 2013 and 2014 
were used for this analysis. 
 
Step 2 (Use Only What’s Reliable): Estimating rates for very small 
communities is difficult, because isolated events can alter rates 
dramatically. It was necessary to determine the point at which data were 
reliable enough to use.83 This was called the threshold of stability. The 
threshold was established to be 3,000 residents. 
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 Since the opioid crisis in Massachusetts accelerated in 2012, no data prior to 2012 was used in the analysis. 
83
 To establish our “threshold of stability,” we looked at the standard deviations of community level rates for 
each of the 4 measures using different population cut points for the communities. Community population size 
was determined using the 2010 US Census. Multiple population cut points were tested to determine the 
appropriate threshold: all communities, 1,000 2,000, 3,000 and 20,000 residents. For all four measures, the 
standard deviation of the rates stabilized once when communities with 3,000 residents or more were 
considered. 
Current Status: Other than 
counts of opioid-related 
deaths (which are unstable 
for smaller communities), 
little is known about the 
burden of the opioid crisis 
in all 351 Massachusetts 
communities. 
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Step 3 (Make Small Towns Seem Bigger): After determining the threshold of 
stability, data for the 75 smallest towns in Massachusetts were adjusted so 
that changes in rates would be similar to a town of 3,000 people.84 
 
Step 4 (Find Data with Similar Patterns): The level of community burden 
was estimated using information about fatal opioid overdoses for residents 
of a community, nonfatal opioid overdoses for residents of a community, 
Naloxone kits distributed to communities, and the number of infants born 
with neonatal abstinence syndrome (NAS) to mothers who lived in these 
communities. These four data points were chosen because they were 
expected to show similar changes over time and across communities. If a 
community was high or low on one measure, it would be similarly high or 
low on others.85 
 
Key Findings: A measure of the overall burden of the opioid crisis on the 
community level was developed using four data points (described above) that 
captured different aspects of the crisis. The map below shows the burden for all 
351 Massachusetts communities divided by quintiles (i.e., five equally-sized 
groups ordered from lowest to highest burden) – the darker the shade, the 
higher the burden of opioid use in that community. 
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 A Poisson probability of the number of actual events occurring in each community was computed for each 
of the 4 measures. That probability was compared to the probabilities computed for rates for a hypothetical 
town of 3,000 people. The rate for the hypothetical town replaced the rate for the smaller community to make 
it more reliable over years.  
85
 The actual rates for larger towns and estimated rates for smaller towns were analyzed using a 
principal components analysis. A one component solution was clearly indicated as it accounted for 
nearly three-quarters of all differences. Therefore, adding together standardized values for the 
four measures was a reliable way to estimate the opioid burden on a community level. 
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Recommendations for Further Analysis: 
 A comprehensive geospatial analysis of opioid burden should be 
conducted at the micro-geographic-level (e.g., census tract, block group, 
block) to identify neighborhood level burden. 
 Hotspot cluster analysis should be conducted at the census tract or 
block group level to identify statistically significant clusters of opioid 
burden on the neighborhood level across Massachusetts. 
 A thorough geospatial analysis should look at the relationship between 
local opioid burden and available services such as pharmacies, SEPs, 
OEND, MAT, detox programs, hospitals, etc.  
 A composite variable for available services should be developed and 
mapped geospatially. Several variables should be considered for this 
composite variable: 
o Numerator: naloxone distribution, number of people receiving 
medication assisted therapy (MAT: methadone maintenance, 
buprenorphine, suboxone), number of people in drug 
detoxification programs;  
o Denominator: number of people with opioid use disorder (OUD) 
 Development of novel variables and analyses to assess access to 
services should be considered:  
o MAT services received per 1,000 fatal overdoses; MAT services 
per 1,000 people with OUD; 
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o Naloxone kits distributed per 1,000 people with OUD 
o Ratio: number of providers to number of people with OUD 
 Statistical models should be considered to identify community-level 
factors associated with opioid burden and access to services.  
 Trends in opioid burden should be examined in order to make estimates 
of future risk on a community by community basis. 
 
 
 
  
Appendix A: Dataset Descriptions 
 
The diagram below shows the 22 datasets linked to produce this report. Sixteen of the data sets were 
linked at the individual level while six data sets provided additional community level data either at the 
town or zip code level. The MassHealth data also included service flags for individuals receiving services 
from the Department of Children & Families, the Department of Youth Services, the Department of 
Developmental Services, the Department of Transitional Assistance, and the Massachusetts Commission 
for the Blind.86  
 
 
 
The remainder of Appendix A provides a description of each of the 22 datasets used for this report. Each 
description outlines the information collected, the frequency, the limitations, the lag time between data 
collection and data availability, the relevance to opioids, and the authorization for collecting the data. 
  
                                                          
86
 With the exception of data from the Department of Transitional Assistance, the data in the service flag fields was poorly 
populated and therefore was not used in this report. 
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Registry of Vital Records and Statistics (RVRS)87 – Death Records88  
What data are collected: Opioid-related deaths are the primary focus of this work and the most basic 
source of this information comes from death certificates filed with the Registry of Vital Records and 
Statistics (RVRS). The official cause of death and the manner of death (i.e., intentional, unintentional, 
or undetermined) are assigned by physicians and medical examiners. Each death certificate also 
includes demographic information such as age, race, Hispanic ethnicity, gender, educational 
attainment, marital status, and occupation. These basic demographics are recorded by the funeral 
director and are typically provided by a family member. 
Availability of data: Mortality information is reported electronically using the Vitals Information 
Partnership89 (VIP). The VIP system is web-based and receives information 24 hours a day seven days 
a week. For analytic purposes, data can be exported from VIP with all the data elements listed above. 
Opioid-related deaths and other complex cases are almost always referred to the Office for the Chief 
Medical Examiner (OCME) for determination of cause and manner of death. This results in a 
reporting lag for these deaths. That said, basic data on demographics is available on a near-real time 
basis. 
Limitations of the data: As legal records, the information recorded on death certificates is 
considered highly accurate. However, some information like race, Hispanic ethnicity, educational 
attainment, marital status, and occupation are not always fully populated. Causes of death from the 
OCME often lag the date of death making some elements of death data less timely than others. 
 
Bureau of Substance Abuse Services (BSAS)90 – Substance Abuse Treatment Data91 
What data are collected: Massachusetts Bureau of Substance Abuse Services (BSAS), of the 
Department of Public Health, is the single state authority responsible for regulating and licensing 
substance abuse treatment providers. The services provided range from acute detoxification to 
residential and outpatient based services. All treatment providers who receive funding from BSAS are 
required to submit data to BSAS to carry out the responsibilities listed under the law. The required 
data fields include but are not limited to client characteristics, enrollment information, disenrollment 
information, services and outcomes. Currently, only treatment providers that receive funding from 
the Department submit this data to BSAS.  
Availability of data: Processing of linked clients also allows us to construct treatment episodes and 
entire client histories. There is a one to two month lag between the time the data are reported and 
the time it is available for analysis/reporting from BSAS. 
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 Accessed at http://www.mass.gov/eohhs/gov/departments/dph/programs/admin/dmoa/vitals/ on 5/19/2017. 
88
 The collection of death certificate data is authorized by MGL Chapter 46. 
89
 Accessed at http://www.mass.gov/eohhs/gov/departments/dph/programs/admin/dmoa/vitals/vitals-information-
partnership-vip.html on 5/19/2017. 
90
 Accessed at http://www.mass.gov/eohhs/gov/departments/dph/programs/substance-abuse/ on 5/19/2017. 
91
 The collection of detailed substance abuse treatment by BSAS is authorized under MGL Ch.111 B and E. All treatment 
providers are required to submit data to BSAS to carry out the responsibilities listed under the law. The regulations 
promulgated to carry out these responsibilities require the providers to submit data in a timely manner. The required data 
fields include but are not limited to: client characteristics, enrollment, disenrollment information, services and outcomes. 
Currently, only treatment providers that receive funding from the Department submit the required data to BSAS.  
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Limitations of the data: The BSAS data set poses several limitations. First, BSAS data does not 
represent all substance abuse treatment provided in the commonwealth. BSAS only collects data 
from its contracted providers. Of the data that is submitted to BSAS, outpatient treatment data is 
incomplete and does not include all non-BSAS paid services. BSAS does not collect data from 
providers that prescribe Vivitrol or from non-contracted Buprenorphine providers. At the time of this 
analysis, Methadone data was incomplete. Due to challenges associated with recent system changes 
related to data submission, some Methadone providers have been unable to submit data. Data 
collected in regards to section 35 commitments are incomplete in the BSAS data set. For example, in 
2015 there were 2,068 Section 35 commitments served in settings outside the scope of data 
submitted to BSAS (e.g. MASAC and MCI Framingham). As a result of these data limitations, it is 
possible that some of the analyses using BSAS treatment data may provide an incomplete picture. 
 
Prescription Drug Monitoring Program (PDMP)92 – Schedule II through V medications93 
What data are collected: Information about filled prescriptions for schedule II through V medications 
is reported electronically each business day to the Prescription Drug Monitoring Program (PDMP) in 
the Department of Public Health’s Office of Prescription Monitoring and Drug Control (OPMDC) by all 
Massachusetts community, hospital outpatient and clinic pharmacies as well as from out-of-state 
mail order pharmacies that deliver to patients in Massachusetts. Schedules II through V medications 
consist of those prescription drug products with recognized potential for abuse or dependence (e.g., 
narcotics, stimulants, sedatives). Consequently, they are among those most sought for illicit and non-
medical use. The specific medication as well as the dosage and the number of pills or amount are 
also captured. In order to facilitate the monitoring of individuals who receive scheduled medications, 
basic identifying information like full name, gender, date of birth, and full address are also recorded 
as well as information about the prescriber and dispensing pharmacy. 
Availability of data: PDMP reporting is comprehensive for pharmacies within the Commonwealth 
with very few instances of non-compliance among pharmacies. PDMP data arrives daily and is 
considered complete and accurate for export and analysis within approximately two weeks. 
Limitations of the data: The PDMP dataset has a few noteworthy limitations. First, methadone clinics 
do not report to the Massachusetts PDMP as they are exempt by statutory language. Specifically, the 
PDMP only collects data on prescriptions dispensed, and methadone in clinics is administered 
pursuant to medical order, not prescription. Methadone is only included when prescribed for pain. 
Second, controlled substance prescriptions dispensed by Veterans Administration (VA) facilities are 
not included. This represents a high risk population and a significant data gap. Third, prescription 
drugs that are obtained illegally (e.g., stolen, purchased on the street, etc.) are a potentially 
significant contributor to the opioid overdose epidemic and are not captured within an individual’s 
PDMP history, but may be captured by the OCME toxicology screens. Finally, a filled prescription 
should not be interpreted to mean that an individual took all or even any of that medication. Linking 
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 Accessed at http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/drug-control/PDMP/ on 5/19/2017. 
93
 The Department of Public Health’s Office of Prescription Monitoring and Drug Control (OPMDC) established the 
Massachusetts Prescription Monitoring Program (MA PDMP) in 1992 pursuant to joint regulations (105 CMR 700.012) with the 
Board of Registration in Pharmacy (247 CMR 5.04). 
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these records with toxicology data can provide some insight into the proportion of scheduled 
medications that are illegally diverted for other purposes than originally intended. 
 
Massachusetts Ambulance Trip Record Information System (MATRIS)94 – Office of Emergency Medical 
Services (OEMS)95 
What data are collected: The Department of Public Health’s Office of Emergency Medicine (OEMS) 
established the Massachusetts Ambulance Trip Record Information System (MATRIS) in December 
2010 as a statewide system collecting emergency medical service (EMS) incident data from licensed 
ambulance services. Under EMS System regulations, ambulance services are required to document 
each EMS call and include the data elements pertaining to the call specifically referenced in an 
administrative requirement issued by OEMS governing the statewide EMS minimum data set. 
MATRIS data elements are based on the National Emergency Medical Service Information System 
(NEMSIS) Version 2.2.1 dataset standard developed in 2005. This includes demographic, clinical, 
operational, and billing data. Demographics required are patient age, birth date, gender, and patient 
home address. Also required are incident type, incident address, dates, times, destination facility 
type, destination facility name, and destination facility address. Patient name is not currently 
required but is submitted approximately 70% of the time. MATRIS can identify nonfatal-opioid-
related events, even when the patient refuses transport to the hospital. MATRIS tracks when 
naloxone was administered either by the EMT or as “prior aid” by other first responders, (fire, police) 
or bystanders (friends, family). Evaluation on interventions provided by EMTs can be performed to 
correlate survival and other outcome rates when linked with outcomes from ED and death data. 
Availability of data: Ambulance incident information is submitted into the MATRIS secure website 
electronically from all licensed ambulance services in Massachusetts within 14 days of the call; 
however frequency of submission varies by service. Many of the larger ambulance services have 
automated daily submission, while others can take longer to submit. There are currently over 6.4 
million ambulance trip records in MATRIS. There were 1.3 million records in MATRIS for incidents 
occurring in both 2013 and 2014. There are 1.4 million for 2015 available for future analysis. 
Limitations of the data: MATRIS has several limitations. The first is that the NEMSIS standard does 
not specifically identify incidents as being opioid-related, but rather “poisoning/ingestion.” The 
second, the data are not uniformly reported by EMS providers. The third limitation is that the overall 
usability of the data submitted by ambulance services varies by provider, with roughly 30% of the 
provided data being partially or completely unusable. These issues are partially mitigated through 
the integration with other datasets listed above. Finally, whether a specific ambulance trip involves 
an opioid overdose is not a simple judgment. The classification of opioid trips was based on an 
algorithm developed in conjunction with the Centers for Disease Control and Prevention. Their 
assistance was invaluable. 
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 For more information see: www.mass.gov/dph/oems/matris 
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 The collection of detailed ambulance trip data by OEMS is authorized under 105 CMR 170.345(B). 
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Registry of Vital Records and Statistics (RVRS)96 – Birth Records97  
What data are collected: The collection and dissemination of this data are to facilitate the 
surveillance of births and birth trends in the state of Massachusetts, including those based on 
demographic information and data on birth outcomes. Data are reported to the Registry of Vital 
Records and Statistics (RVRS) by all licensed birthing hospitals and birthing centers and by city and 
town clerks if they are establishing a home birth that occurred in their city/town in Massachusetts. 
The birth data contains identifying information about the parents of record and the child. These data 
are critical to understand the health risk to a mother who delivers a Substance Exposed Newborn 
(SEN) or an infant with Neonatal Abstinence Syndrome (NAS).  
Availability of data: Natality information is reported electronically using the Vitals Information 
Partnership (VIP).98 The VIP system is web-based and receives information 24 hours a day, seven days 
a week. Substantial quality control efforts are required to assess the accuracy and completeness of 
birth records. As a result, the final dataset of birth records is usually available by May of the following 
year. 
Limitations of the data: As legal records, the information recorded on birth certificates is considered 
highly accurate. However, some information like race and Hispanic ethnicity are not always fully 
populated.  
 
Massachusetts Cancer Registry (MCR)99 – Cancer Staging100 
What data are collected: The Massachusetts Cancer Registry (MCR), a database managed by the 
Department of Public Health, is a population-based registry that tracks the incidence of cancer within 
the Commonwealth. Since 1982, the MCR has captured key data elements such as date of diagnosis 
and cancer stage at diagnosis, in addition to various demographic data elements. For this purposes of 
this work, MCR data was included because palliative treatment for late stage cancers often includes 
the use of opioid medications to control pain. Being able to distinguish those cases of high opioid use 
for cancer treatment from cases where an individual may be abusing prescription medications was 
critical to this study.  
Availability of data: Reporting facilities are required to report case level data to the MCR within 180 
days of diagnosis or first date of patient interaction. Analysis of supporting documentation related to 
determining the stage of a cancer also takes considerable time. Typically, MCR data availability lags 
the calendar by approximately two years. 
Limitations of the data: Defining the stage of a cancer is not an exact science. It is based on a 
number of written reports and laboratory tests. Furthermore, not all cancers cause significant pain 
even in late stages. These data can provide an indication that medications may have been prescribed 
for pain but they cannot definitively rule out the possibility that there was underlying abuse. 
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 Accessed at http://www.mass.gov/eohhs/gov/departments/dph/programs/admin/dmoa/vitals/ on 5/19/2017. 
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 The collection of Confidential Birth Information is authorized under 105 CMR 350.000. 
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 Accessed at http://www.mass.gov/eohhs/gov/departments/dph/programs/admin/dmoa/vitals/vitals-information-
partnership-vip.html on 5/19/2017. 
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 Accessed at http://www.mass.gov/eohhs/gov/departments/dph/programs/admin/dmoa/cancer-registry/ on 5/19/2017. 
100
 The collection of detailed cancer incidence and staging by the MCR is authorized under Chapter 111, Section 111B. 
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Office of the Chief Medical Examiner (OCME)101 – Circumstances of Death and Toxicology Reports102 
What data are collected: The OCME, a part of the Executive Office of Public Safety and Security, 
gathers a great deal of information about unattended and other deaths where the underlying causes 
may not be apparent. Not of all of the information collected is relevant to opioid-related overdose 
deaths, so the work reported here has focused on the circumstances of death recorded on the OCME 
intake forms and the toxicology reports used to determine the cause of death. The data field labeled 
“circumstances of death” is a brief narrative that describes the setting and environment of an 
unattended death. It is often written by the State Police in the case of acute opioid-related 
overdoses. These narratives are analyzed by searching for the presence of key words. The toxicology 
reports describe the presence of hundreds of specific chemical compounds that might be found in 
the body of the decedent. This study has focused primarily on the presence of natural and synthetic 
opioids. 
Availability of data: The intake forms that contain the circumstances of death narratives are usually 
available within about 72 hours of a case being accepted by the OCME. Toxicology screening and 
confirmatory tests are conducted by the Crime Laboratory run by the Massachusetts State Police as 
well as the NMS Labs (Willow Grove, PA). Toxicology tests lag the date of death by about 60 days. 
Limitations of the data: Written narratives will provide initial impressions of the circumstances of 
death. As first impression, these can be misleading in some cases. Final causes of death must be 
provided by physicians and medical examiners. Toxicology results can be extremely complex to 
interpret. Levels of drugs found a decedent’s tissue are affected by the timing of the test, the type of 
tissue, and other factors. Many drugs also metabolize into a variety of different chemical 
compounds. For all these reasons, toxicology results are generally examined in broad categories to 
simplify interpretation. OCME data are connected directly to the death records using name, date of 
birth and date of death. A unique OCME ID number is used to link to toxicology reports. Finally, the 
vast majority of the toxicology records for early 2013 were only available on paper and thus not 
practical to include in this report. 
 
Case Mix Database103 – Inpatient hospitalization, emergency department visits, and outpatient 
observations managed by the Center for Health Information and Analysis (CHIA)104 
What data are collected: The Case Mix data contains all inpatient hospitalizations, emergency 
department visits, and outpatient observation in the state. Massachusetts acute care hospitals are 
required to submit Case Mix data to the Center for Health Information and Analysis (CHIA) in order to 
track disease burden and associated costs statewide. Detailed information is available for each 
encounter, including geography (e.g., zip code, town, county, state, country), demographics (e.g., 
age, race, ethnicity), and costs by service (e.g., medical/ surgical, behavioral health), admission and 
discharge dates, diagnosis, and the facility providing patient care. Case Mix data can identify 
individuals who received past treatment for a substance overdose including healthcare encounters 
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 Accessed at http://www.mass.gov/eopss/agencies/ocme/ on 5/19/2017. 
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 The collection of death certificate data is authorized by MGL Chapter 38. 
103
 Accessed at http://www.chiamass.gov/case-mix-data/ on 5/19/2017. 
104
 Massachusetts acute care hospitals are required to submit Case Mix data in accordance with Regulation 114.1 CMR 17.00. 
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associated with detoxification, psychiatric care, and overdose based on procedures rendered or 
diagnoses made when these services are offered by acute-care hospitals.  
Availability of data: The Center for Health Information and Analysis (CHIA) receives data quarterly. 
Significant work is required to clean and harmonize the data across hospitals. As a result, there is 
approximately a one year lag between final data submission to CHIA by acute care hospitals and 
receipt of the data by DPH and other approved organizations.  
Limitations of the data: The Case Mix data does not include hospital services rendered to 
Massachusetts residents by non-Massachusetts hospitals or hospitals operated by the Veterans 
Administration (VA), thus reducing the observable analytic universe. Similarly, CHIA does not 
currently collect information from behavioral health hospitals. Demographic data included in Case 
Mix is not considered as accurate as those recoded on birth of death records. Consequently, the 
linkage of these records to other datasets may be incomplete. Furthermore, the coding of 
encounters for overdose or for behavioral health services is not considered fully complete. Finally 
and possibly most important for the Chapter 55 project is that Case Mix data are available on a 
Federal fiscal year. The most recent data available is through 9/30/2014 which means that any data 
on nonfatal overdoses, substance abuse treatment, or mental health diagnosis codes will not be 
captured in the final three months of the study period. The low linkage rate for infant records 
produced a smaller number of NAS-related records for mothers. 
 
Non-Scheduled Pharmacy Claims105 – Massachusetts All Payer Claims Database (APCD)106 
What data are collected: The Massachusetts All Payer Claims Database (APCD) is managed by the 
Center for Health Information and Analysis (CHIA). The APCD contains health and pharmacy 
insurance claims data from the approximately 80 private health care payers, public health care 
payers (including Medicare and MassHealth) and publicly-supported managed care organizations and 
senior care organizations across the entire state of Massachusetts. The APCD insurance eligibility files 
include basic identifying information like full name, address, gender, date of birth, race, ethnicity, 
and Social Security number. Most APCD data requested from CHIA focused on pharmacy claims for 
non-scheduled medications. 
Availability of data: The APCD is overseen by CHIA, the independent state agency responsible for 
collecting, cleaning, maintaining, and managing access to the data. Data are reported out once a year 
and each report contains all data from the previous calendar year. The newest version is available 
approximately six months after the close of the preceding calendar year. 
Limitations of the data: The APCD forms the backbone or spine of the linked datasets. Its 
completeness and accuracy are critical to the entire effort. In recent years, CHIA has expended 
significant resources to link records across payers. The current APCD contains roughly 15 million 
unique records which is substantially above the 6.3 million residents in Massachusetts. Most of these 
records are single records unconnected to a full set of identifiable records. Other analyses 
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 Accessed at http://www.chiamass.gov/ma-apcd/ on 5/19/2017. 
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 CHIA has statutory authority to collect data from both public and private health care payers under Massachusetts General 
Laws Chapter 12C, section 10. By July 2010, Regulations 114.5 CMR 21.00 and 114.5 CMR 22.00 formally established the APCD 
in Massachusetts. 
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undertaken for this project suggest that the unique records prepared for the APCD serve the purpose 
intended. Other known limitations of the APCD include exclusions such as Workers’ Compensation, 
TRICARE/Veteran’s Health Administration, and the Federal Employees Health Benefit Plan claims. 
Additionally, uninsured individuals (approximately 3% of the state’s population) are not captured. 
Finally, healthcare services provided but paid for out of the patient’s own finances, e.g., cash 
payment for a convenience care clinic service like a strep throat culture, are excluded because these 
services do not generate claims. 
 
Department of Correction (DOC)107 – Incarceration and Treatment108 
What data are collected: The Department of Correction (DOC), a part of the Executive Office of 
Public Safety and Security, is required by statute to maintain adequate records of persons committed 
to the custody of the Department. In addition, DOC must establish and maintain programs of 
research, statistics, and planning, and conduct studies relating to correctional programs and 
responsibilities of the Department. To achieve those goals, DOC maintains a database of individuals 
incarcerated in Massachusetts prisons. This database includes the substance abuse treatment 
received by prisoners. Identifiers like full name, gender, date of birth and Social Security numbers are 
also included. 
Availability of data: As releases from prison are routine, these data are kept current. Releases from 
January 1, 2011 to December 31, 2015 were included. 
Limitations of the data: DOC data includes incarcerations for those in prison and does not include 
data for people in jails or houses of correction (HOC). That data is separate and does not include all 
the same information as the DOC data. Analyzing only the DOC data could yield misleading results 
since HOC serves a higher volume of inmates per year in comparison to DOC, primarily due to shorter 
sentences and those waiting trial within HOC. An additional limitation arises if residents of 
Massachusetts are incarcerated outside of Massachusetts as that data is not captured by DOC. 
 
Department of Mental Health (DMH)109 
What data are collected: The Department of Mental Health, as the State Mental Health Authority, 
assures and provides access to services and supports to meet the mental health needs of individuals 
of all ages, enabling them to live, work and participate in their communities. The Department of 
Mental Health (DMH), under the umbrella of the Executive Office of Health and Human Services 
(EOHHS), is required by statute to maintain adequate records of persons receiving services of the 
department. This database includes psychiatric hospitalizations, substance abuse treatment and the 
desire for change and stage of change, loss of housing, incarceration, use of crisis stabilization beds 
and employment status between January 1, 2011 and December 31, 2015. Identifiers included 
gender, race, and age. 
Availability of data: Different programs and services provided by DMH are kept current and are 
available for the period from 1/1/2011 through 12/31/2015. 
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 Accessed at http://www.mass.gov/eopss/agencies/doc/ on 5/19/2017. 
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 The collection of detailed incarceration data by DoC authorized under MGL c. 124, s. 1(j) and MGL c. 124, s. 1(k). 
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 Accessed at http://www.mass.gov/eohhs/gov/departments/dmh/ on 5/19/2017. 
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Limitations of the data: The Chapter 55 DMH data only includes data for services provided by DMH 
such as Community Based Flexible Supports (CBFS) and Clubhouse Coalition programs. It does not 
include routine or crisis mental health services provided in hospitals, emergency departments, and 
the private offices of licensed mental health providers. Some of these data can be found in the APCD 
and Case Mix data sets. 
 
Department Housing and Community Development (DHCD)110 – Family Homelessness 
What data are collected: DHCD's mission is to strengthen cities, towns and neighborhoods to 
enhance the quality of life of Massachusetts residents. This agency provides leadership, professional 
assistance and financial resources to promote safe, decent affordable housing opportunities, 
economic vitality of communities and sound municipal management. DHCD collects and maintains 
data on all persons receiving services from the Department. For this report, DHCD created a subset of 
the records of families (heads of household) who received services from the Emergency 
Assistance Program between January 1, 2011 and December 31, 2015. Identifiers included 
gender, race, age, veteran status and disability.  
Availability of data: Different programs and services provided by DMH are kept current and are 
available for the period from 1/1/2011 through 12/31/2015.  
Limitations of the data: While DHCD offers supportive services for individuals who are homeless, the 
Chapter 55 data only includes services provided to families. The linkage to the APCD is made through 
the listed Head of Household in the DHCD data set. This may represent an underestimate of housing 
instability even for individuals within families because only the head of household is linked to the 
APCD. 
 
Department of Veterans’ Services (DVS)111 – Benefits Programs 
What data are collected: The mission of the Department of Veterans’ Services (DVS) is to be the 
chief advocate for the nearly half-million veterans of the Commonwealth and their families. DVS 
establishes policy, proposes legislation, ensures that adequate funding for veterans’ programs is 
included in the Governor’s budget, and represents the interests of veterans in matters coming before 
the General Court. In addition, DVS represents all state agencies and individual veterans before the 
federal Department of Veterans Affairs in securing federal compensation and other benefits that 
might be available. DVS collects information of all Massachusetts veterans receiving benefits through 
DVS. Among other data, DVS collects data on persons who received DVS medical, housing or other 
benefits from DVS through communities. Identifiers included name, date of birth, social security 
number, race, gender and address.  
Availability of data: For Chapter 55, DVS provided DPH with payment information for medical, 
housing or other benefits made between January 1, 2011 and December 31, 2015. 
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Limitations of the data: These data include only benefits directed to Massachusetts veterans by DVS. 
Any federal, private, other donations are not captured in the DVS data set. Therefore, these data will 
be an underestimate of all services provided to Massachusetts veterans. 
 
MassHealth112 – Opioid Related Services for the Massachusetts Medicaid population 
What data are collected: In Massachusetts, Medicaid and the Children’s Health Insurance Program 
(CHIP) are combined into one program called MassHealth. MassHealth maintains and updates 
reports quarterly on member enrollment, application activity and services provided. Identifiers 
included name, date of birth, social security number, gender, race and city of residence. Variables 
included disability status, type of MassHealth Plan and coverage type, dually eligible status (Medicare 
and Medicaid), and number of enrollment days per month. Variables also included if client received 
services from Department of Developmental Services, Department of Mental Health, Department of 
Children & Families, Department of Transitional Assistance, Department of Youth Services, and 
Massachusetts Commission for the Blind. Using CCS, ICD-9 and 10 codes other variables included 
inpatient psychiatric hospital, semi-acute hospital, specialty hospital for substance use disorder, 
Serious Mental Illness diagnosis, Mental Illness diagnosis, Substance Use Disorder diagnosis. Payment 
variables included MassHealth payments, patient payment amounts, third party payment amounts, 
pass through claim payments and claims passing through MassHealth for federal match. Unstable 
housing was an additional variable (defined as three or more street addresses in a calendar year).  
Availability of data: MassHealth medical claims are included in the APCD dataset. The additional data 
provided by MassHealth for Chapter 55 includes information on type of coverage, disability status, 
payment amounts, specific types of opioid related services and whether an individual was served by 
any of the following agencies: Department of Developmental Services, Department of Mental Health, 
Department of Children & Families, Department of Transitional Assistance, Department of Youth 
Services, and the Massachusetts Commission for the Blind. 
Limitations of the data: As with any medical claim, the information contained in the MassHealth 
records cannot be tied directly to a specific clinical judgment about an individual or about that 
person’s behavior. For example, diagnosis codes may be included for the purposes of billing and may 
not provide a full picture of a patient’s health. Similarly, the fact that a payment was made for a 
medication cannot guarantee that an individual used the medications as prescribed. Opioid -services 
tracked and paid for by MassHealth will not include any services privately paid for or provided free of 
charge; therefore, these services could be underrepresented if only MassHealth records are included. 
Finally, the information provided by MassHealth only includes person covered by MassHealth for the 
period they were covered. If a person had interruptions in their MassHealth, equivalent services may 
have been provided by other insurers or entities for which we do not have comparable data. 
 
Massachusetts Sheriff’s Association113 – Incarceration in Houses of Correction 
What data are collected: It is the mission of the Massachusetts Sheriffs' Association to promote, 
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advocate and support the office of sheriff in all fourteen counties of the Commonwealth, to secure 
their cooperative working relationship with one another, to enhance their work as the chief law 
enforcement officers of the counties, and to advance efforts to unify their efforts in policy 
development, operations and training while preserving the autonomy of each office. The Houses of 
Correction operate on a county level. They are required to track releases to the public through the 
Executive Office of Public Safety and Security. Individual releases are the basis for the data included 
in Chapter 55. The information includes basic identifiers as well as specific release dates. 
Availability of data: The Chapter 55 data set include releases of sentenced offenders between July 1, 
2011 through December 31, 2015 as reported by the county sheriffs’ departments. These data are 
reported to the Massachusetts Executive Office of Public Safety (EOPSS) quarterly. 
Limitations of the data: Incarceration dates are not reported for all county releases, so the full 
period of incarceration is not available for the data set. Hampshire and Berkshire counties did not 
submit data for FY2012 quarter 2, and Worcester county did not provide offender date of birth for 
CY2012 through CY2013 Q4, so their information is excluded for this analysis. These data should be 
combined with data from the Department of Correction to provide a fuller perspective of 
incarcerations for Massachusetts residents. However, residents of Massachusetts incarcerated 
outside of Massachusetts are not captured. 
 
Community Level Data 
Census: 
What data are collected: name of city/town, EOHHS Region, EMS Region, total population, age 
group (18 age groupings), median age, gender, race, spoken language, unemployed individuals, 
food assistance received, income below poverty level, median household income, own or rent, 
and education level.  
Availability of data: Data from the American Community Survey, five year-Estimates: 2006-2010 
Limitations of the data: Since the data from a community or a zip code are applied to all 
residents of that community or zip code, the data can help in understanding the context in 
which an individual lives but not whether that data applies to any specific individual in the data 
set. 
 
Naloxone: 
What data are collected: Data from the MDPH Naloxone program from 2011-2015 including 
enrollments by month and town, refills by month and town and rescues by month and town.  
Availability of data: 2011-2015 by city/town 
Limitations of the data: Since the data from a community or a zip code are applied to all residents 
of that community or zip code, the data can help in understanding the context in which an 
individual lives but not whether that data applies to any specific individual in the data set. 
 
Needle Exchange: 
What data are collected: The Bureau of Substance Abuse Services has gathered data on needle 
exchange programs by town.  
Availability of data: 2011-2015 by city/town 
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Limitations of the data: Since the data from a community or a zip code are applied to all residents 
of that community or zip code, the data can help in understanding the context in which an 
individual lives but not whether that data applies to any specific individual in the data set. 
 
MDPHnet Depression Scores by Town: 
What data are collected: MDPHnet is a distributed network of EHR-based data depositories. 
MDPHnet utilizes custom algorithms to detect cases that integrate diagnosis codes, laboratory 
tests, prescriptions, and other clinical indicators to accurately identify key conditions. In this case, 
MDPHnet was used to produce town level estimates of depression. 
Availability of data: 2011-2015 by city/town 
Limitations of the data: Since the data from a community or a zip code are applied to all residents 
of that community or zip code, the data can help in understanding the context in which an 
individual lives but not whether that data applies to any specific individual in the data set. 
 
Drug Seizure Data: 
What data are collected: Massachusetts Executive Office of Public Safety & Security records the 
number of incidents where drugs were seized between 2011-2015 by month. Each seizure is 
recorded by town. Variables included the type and amount of each drug seized.  
Availability of data: 2011 to 2015. 
Limitations of the data: These data report the number of incidents where drugs were seized, 
many may have resulted in arrests but not all of them.  
 
ICE (Index of Concentration at the Extremes): 
What data are collected: There are three ICE measures by census tract – one for income, another 
for race/ethnicity and the third which combines race/ethnicity. ICEinc sets as the extremes the 
American Community Survey household income categories that most closely approximate 
cutpoints for the US 20th and 80th household income percentile, currently <$25k and >=$100k. 
ICErace sets as the extreme groups persons who self-identify as non-Hispanic White vs. non-
Hispanic Black, over the total population for whom race/ethnicity data are available. ICEwbinc 
combines race/ethnicity and income and sets as the extreme groups non-Hispanic White persons 
whose household income is great than or equal to the 80th income percentile vs. non-Hispanic 
Black persons in households below the 20th income percentile, over the total population for 
whom data on race x income are available.  
Availability of data: American Community Survey five year estimates (2011- 2015). 
Limitations of the data: Since the data from a community or a zip code are applied to all residents 
of that community or zip code, the data can help in understanding the context in which an 
individual lives but not whether that data applies to any specific individual in the data set. 
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Appendix B: Data Linkage 
 
Data linkage for the Chapter 55 work was conducted by the Center for Health Information and Analysis 
(CHIA) in consultation with the Department of Public Health (DPH). Ten levels of matches were tested 
between individual Chapter 55 datasets and identifiers found in the All Payer Claims Database (APCD). 
All matches were deterministic. A conservative approach to matching was used, so no “near” or “close” 
matches were considered. In other words, all successful matches had to be exact at one of ten 
levels. The complete matching scheme is described below. The most reliable match is a “1,” and 
so on down the chart to the least reliable, a “10.”  
 
 
Match Level Identifiers To Be Matched 
1 Exact match on first name, last name, Social Security number, gender, 
birth date, street address #1, street address #2, town of residence, and zip 
code. 
2 Exact match on last name, Social Security number, gender, birth date, 
town of residence, and zip code. 
3 Exact match on Social Security number, gender, and birth date. 
4 Exact match on first name, last name, gender, birth date, street address 
#1, street address #2, town of residence, and zip code. 
5 Exact match on first name, last name, gender, birth date, town of 
residence, and zip code. 
6 Exact match on first name, last name, gender, and birth date. 
7 Exact match on first name, last name, gender, and birth date 
8 First and third letters of first name, first and third letters of last name, 
gender, birth date 
9 Street address #1, street address #2, town of residence and zip code 
10 Exact match on first name, last name, and birth date 
 
 
CHIA processed each Chapter 55 file independent of all other files. To speed the process of the linkage 
work, there was no requirement for CHIA to perform data standardization or to deduplicate the data 
within or across files. Since data fields, collection methods, oversight, and quality vary from source to 
source – and even record to record – it is possible that “John Smith” got a Level 1 match in File1 
but then the same “John Smith” appeared twice in File2, getting a Level 2 and a Level 3 match due to 
algorithm rules and/or missing data. Alternatively, the various John Smiths may not be related. 
 
Without a focused deduplication effort, or a secondary weighted probabilistic match, it is impossible to 
know how often this might have occurred. Other tests of reliability of the matching scheme indicated 
that this was not a frequent occurrence. If duplicates were found within a file, each of these records was 
assigned the same project-specific ID. A summary of the matches across all datasets can be found in 
table below. 
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1. All Payer Claims Database 100.0% 
2. Births Records linking Mothers (Vitals) 91.7% 
3. Bureau of Substance Abuse Services (Treatment) 88.6% 
4. Cancer Registry 88.3% 
5. Case Mix (Hospital, ED, and Outpatient Records) ~70.0%114 
6. Deaths Records (Vitals) 96.7% 
7. Department of Housing & Community Development 82.6% 
8. Department of Mental Health 97.8% 
9. Department of Correction 89.7% 
10. Department of Veterans Services 78.4% 
11. Houses of Correction (MA Sheriffs’ Association) 81.8% 
12. MassHealth 99.8% 
13. Massachusetts Ambulance Trip Information System (MATRIS) 71.1% 
14. Office of the Chief Medical Examiner 96.7% 
15. Prescription Drug Monitoring Program 92.3% 
 
 
After reviewing the detailed matching data for each table, it was determined that match level 9 was too 
vague to be useful. It was dropped from consideration for record level matches. That issue aside, the 
matching procedure described above produced matches across all the tables in that data set that ranged 
from 71.1% on the low end for MATRIS to above 95% on the high end for the APCD (100%), Death 
records from the Registry of Vital Records and Statistics (96.7%), Department of Mental Health (97.8%), 
and MassHealth (99.8%).115
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 Case Mix records are stored without the usual complement of identifiers making estimates of linkage rates difficult to 
compute. Comparisons of non-fatal events in raw Case Mix were made with those same events in the linked data set. 
Approximately 30% more nonfatal opioid events were found in the raw records, thus the estimate of a 70% linkage rate. 
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 Data from Partners Healthcare for a project proposed by Harvard School of Public Health and Partners was also linked to the 
APCD data.  Since this data was not available to other researchers, it is not included in the table above. 
  
Appendix C: Data Privacy and System Architecture 
 
A determination was made at the outset of the Chapter 55 project to be able to examine all datasets in 
relation to each other. This required the development of a linkage or crosswalk so that individuals in one 
set could be located in the others, yet without revealing the identity of the matched person. The privacy 
concerns about holding, managing, and processing direct identifiers for so many sensitive datasets are 
considerable, and the processes developed to address these concerns were both thoughtful and 
innovative. In order to protect the privacy of the individual datasets, four approaches were used: 
 Encryption: All data were encrypted in transport and at rest.  
 De-identification: Direct identifiers were removed from each dataset prior to analyst access. 
The unique identifiers randomly generated for individuals were project-specific, meaning that no 
record IDs could be used to trace information back to any dataset held by any data owner now 
or in the future. 
 Securing the Server: The server on which the Chapter 55 datasets were stored was secured so 
the likelihood of unauthorized access was minimized to the extent possible. 
 Preventing Misuse by Analysts: Additional restrictions were placed on authorized access to the 
server on which the Chapter 55 datasets were stored in order to minimize the likelihood of 
intentional or unintentional misuse of the data. 
Each of these approaches is described briefly below.  
 
Encryption  
Given the sensitivity of the data involved in the Chapter 55 analysis, multiple levels of encryption were 
used with the intent to limit data access to only authorized parties. Whenever data was stored at rest, 
whether on the server or other hard media, it was protected by at least 256-bit encryption and industry-
standard strong passwords. Further, whenever data needed to be transported – for example between 
DPH and CHIA – it was placed in an encrypted file container on physical media that used 
hardware-based encryption. This doubly-encrypted drive was then manually transported by a trusted 
and authorized team member to its destination and hand-delivered to the proper recipient, or similarly 
retrieved for a return trip. 
 
De-identification 
Chapter 55 datasets are not truly linked in the most commonly used sense of that word. In most cases, 
linkage implies a merger of datasets. For Chapter 55, a crosswalk is developed between datasets but the 
datasets themselves were never actually merged. This is an important distinction. By not merging data, 
it is argued that risk of re-identification of individuals who have information in two or more datasets is 
minimized. Furthermore, the unique identifiers contained in each dataset are not found in any other 
project. Thus, if any breach of data or transmission protocol occurred, then the data could not be linked 
back to any source data file. 
 
The specific steps taken to minimize of the risk to data privacy through de-identification are below. See 
Figure F.1 for a visual depiction of this process. 
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1) A pool of roughly 54 million random, non-sequential, 20-digit IDs (Random IDs or RIDs) was 
created at DPH. This number of values was sufficient to assign to every record of each of the 
constituent Chapter 55 raw datasets an ID that was unique across the entire project.  
2) With RIDs affixed, each dataset was divided into two parts: direct identifiers (Identifier set) and 
analytic data (Analytic set). The only common information across both was the RID. The 
Identifier sets were hand delivered to CHIA. As noted under the Encryption section, all data was 
encrypted using 256-bit AES encryption with strong protection consistent with EOHHS and 
MassIT policy regarding password contents and length. 
3) Distinct from DPH’s RID-creation effort, CHIA created an extract of the All Payer Claims Database 
(APCD) that included only the fields to be used for the linkage scheme matching (Appendix D), 
plus an additional project-specific ID (PID). This PID was a random unique 20-digit number. It 
was in no way related to, nor derivative of, CHIA’s Master Person Index (MPID) or any other 
persistent identifying code. This master extract-plus-PID is known as the APCD-Spine. 
4) For each Identifier set, CHIA compared each record to the APCD-Spine. (For additional details on 
the data linkage, please see Appendix D.) Where a match was found, the PID and match level 
were associated with the RID from the Identifier set.  
5) Upon confirmation from CHIA that an Identifier set was successfully matched to the APCD-Spine, 
DPH then deleted that Identifier set from its server. 
6) The result set of matched PID/RID and match level were returned to DPH through the same 
secure mechanism as the delivery of the Identifier sets.  
7) The RIDs within the returned result set were used to appropriately assign PIDs (and match 
confidence) to matching records in the Analytic sets. This allows the Analytic sets to be de-
identified, but also connectable across datasets. 
8) Because DPH had deleted the Identifier set, it was never in possession of the PID, RID and direct 
identifiers at the same time. 
9) After assigning the PIDs to the Analytic sets, DPH securely delivered each Analytic file to the 
Massachusetts Information Technology Center (MITC) to be securely loaded onto the 
designated server.  
10) In order to prevent merging of data, the project-specific identifiers and the analytic files for each 
Chapter 55 dataset were permanently stored in separate folders.  
11) After all Chapter 55 Identifier sets have been matched and the Chapter 55 project no longer 
needs the APCD-Spine, CHIA will then delete it, destroying any connection between direct 
identifiers and PIDs at CHIA. 
  
Figure C.1: Step by step process for transferring data securely from DPH tp CHIA to MITC 
 
  
  
Securing the Server 
There were three main goals in securing the SAS server: 
1) Develop a clear audit process. 
2) Ensure proper encryption for the different needs of the users. 
3) Make it so that it was possible to handle more than a small number of group types in the 
system. 
These three goals were achieved in the following manner: 
 The disk partition on which the Chapter 55 data was stored was encrypted using LUKS (Linux 
Unified Key Setup). Linux is the open-source version of the UNIX operating system and LUKS is 
the standard hard disk encryption method for Linux servers. 
 To provide further flexibility in the design of the secure data ecosystem to the needs of the 
Chapter 55 project, Red Hat Enterprise Linux version 6.0 was used.  
 Accounts were authenticated by LDAP, which is the MITC standard, and account creation was 
handled through specific (not automated) requests to the MITC Linux team. 
 A unique mount point for the Chapter 55 project was created so that only group participants 
could gain access. 
 The interface for Chapter 55 work was through the web server interface with data encrypted at 
rest including all individual work files. 
 An audit process was implemented to record when and who was doing maintenance on/for SAS.  
 All inbound requests to the server were blocked unless the requestor was on a pre-approved 
whitelist. The firewall restricted access to specific ports on the server. Ports were continuously 
monitored. 
 
Preventing Misuse by Analysts: 
To minimize the risk of misuse of Chapter 55 data by authorized users, the following processes were 
implemented as what has been collectively termed a Privacy Shield. 
 Access to Chapter 55 data was only permitted using Enterprise SAS Studio software 
 Only authorized users were given User IDs and passwords to access the Chapter 55 data. 
 Authorized users were required to demonstrate that DPH-required privacy and confidentiality 
trainings were up to date. 
 Only de-identified Analytic sets were accessible by analysts. 
 Analysts had “read only” access to Chapter 55 datasets. Writes were not permitted. 
 Analysts were not permitted to see the raw Chapter 55 Analytic data. This was accomplished by 
turning off the ability of authorized users to open and view raw Analytic data files. 
 Analysts were not permitted to see small cell sizes. The common SAS procedure for producing 
counts and cross-tabulations (PROC FREQ) was altered so that it masked (by displaying asterisks) 
any cell count that was between one and 10. 
 All temporary SAS work files were deleted in one of three ways. If shutdown of a process was 
typical, files were deleted upon shutdown. If shutdown was atypical (e.g., power outage), the 
system searched for orphaned work files every 15 minutes and these files were deleted. If any 
data query was open for more than 72 hours, then the system administrator could manually 
shut down a process which would delete any associated SAS work files. 
 An audit process of all commands issued to SAS was implemented. Logs were checked to ensure 
that no analyst made any attempt to export, print, or otherwise view any Chapter 55 data. 
 
See Figure C.2 for a visual depiction of the Chapter 55 Data Warehouse. 
 
  
Figure C.2: Data analyst access to Chapter 55 datasets through a secure hardware and software Privacy Shield. 
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Appendix D: Supplemental Data 
Section 1: Chapter 55 Approved Projects 
 
Project Title: Linking Toxicology at Death with Prescription Monitoring Program Records: Implications 
for Defining Fentanyl and Heroin-related Deaths 
Project Lead: Alex Walley (BMC)  
Project Team: Marc LaRochelle (BMC), Traci Green (Brown), DPH Resources 
Approved: 1/30/2017 
Project Summary: Specific opioid toxicology in cause of deaths records has been imprecisely and 
inconsistently defined and reported across medical examiner jurisdictions. Specifically, likely heroin-
related overdoses are inconsistently distinguished from morphine-related deaths because they have 
similar toxicology. Furthermore, fentanyl-related deaths have been classified as “prescription opioid-
related” although young evidence has demonstrated that the fentanyl that is causing increased 
overdoses is illicitly made outside of the pharmaceutical fentanyl distribution system. Study will 
thoroughly examine historical and active prescribing along with post-mortem toxicology and how timing 
of prescriptions relates to fatal and non-fatal overdose. What fraction of overdoses with opioid A are 
attributable to opioid A prescriptions versus other sources for opioid A? 
 
 
Project Title: Factors Associated with Overdose Death Among Inpatient Detoxification Patients 
Project Lead: Alex Walley (BMC)  
Project Team: Marc LaRochelle (BMC), DPH Resources 
Approved: 1/30/2017 
Project Summary: The population of patients who undergo inpatient detoxification represents a narrow, 
but specific group of those who have baseline risk for opioid overdose. People who seek inpatient 
detoxification are trying to reduce their risk of overdose; however, detox lowers opioid tolerance, thus 
increases overdose risk in the immediate post-detox time period. Patients who seek inpatient 
detoxification are both easy to define and recognize in the dataset, as well as, relatively easy to reach in 
the real world if an intervention comes out of this project. The protective and risk factors will be data 
elements that are both available in the datasets and have clinical and public health implications. This 
study will examine the protective and risk factors associated with different modalities of substance use 
disorder treatment. 
 
 
Project Title: Developing a Predictive Model for Homelessness in Massachusetts and Relating Risk 
Estimates to Fatal and Non-Fatal Opioid Overdose 
Project Leads: Tom Byrne (BU) 
Project Team: Marc Dones (C4SI), Travis Baggett (BHCHP), David Smelson (UMASS Med), Asaad Traina 
(HSPH), Abraar Karan (HSPH), DPH Resources 
Approved: 1/30/2017 
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Project Summary: Homelessness has been related to substance abuse, low education levels, 
incarceration status, co-morbidity with other chronic conditions, financial catastrophe, and other 
factors. Identifying the homeless or those at risk of homelessness is challenging because we do not have 
data directly from homeless shelters, nor is there a direct flag for “homelessness” in most databases. 
The study will use logistic regression models to identify data patterns associated with homelessness. 
This predictive model of homelessness will be used to assess ongoing risk of fatal and non-fatal opioid 
overdose for this population. 
 
 
Project Title: Multivariate Analysis of Risk Factors for Death Using Data from the PDMP and Fatal 
Overdoses 
Project Lead: Carly Levy (MCPHS)  
Project Team: Abhidnya Kurve (MCPHS), Roger Studd (MCPHS), Rania Mekary (MCPHS), Francis 
Melaragni (MCPHS), DPH Resources 
Approved: 1/30/2017 
Project Summary: This application proposes to develop a PDMP-specific risk model. All potential factors 
for risk will be examined and included in a multivariate model if they are supported by the data. The 
goal is to develop a tool or alert system that could be incorporated into the PDMP to guide prescribers 
and pharmacists about risks linked specific patients. All algorithms will be self-contained in that they 
would only utilize PDMP data to compute risk assessments on which alerts would be based. 
 
 
Project Title: Examination of opioid prescriptions across the VA and non-VA systems to reduce fatal and 
non-fatal opioid overdoses in Massachusetts  
Project Lead: Guneet K. Jasuja (BU/ Bedford VA Medical Center)  
Project Team: Omid Ameli (Bedford VA), David Smelson (UMASS Med), Dan Berlowitz (Bedford VA), 
Donald R. Miller (BU), Keith McInnes (BU), Adam Rose (RAND), Jim Burgess (BU), Avron Spiro (BU), DPH 
Resources 
Approved: 1/30/2017 
Project Summary: Veterans may be at particular risk for opioid overdose given that they have high rates 
of pain that is often treated with prescription opioids. Further, many Veterans are “dual users” who get 
both VA and non-VA medical care, and this dual use has been shown to increase risk for adverse 
outcomes in other areas of care. Thus, the objective of these analyses is to examine whether Veterans 
who receive prescriptions for opioids in both systems (VA and non-VA) are at an increased risk of fatal 
and non-fatal opioid overdose as compared to Veterans who receive all their opioids in one system. 
Further, we will examine whether the pattern and times of transition of opioid prescriptions between 
VA and non-VA systems would increase this risk of opioid overdose.  
 
 
Project Title: Developing a Dynamic Model for Predicting Opioid Overdoses with the Opportunity to 
Identify Effective Points of Intervention 
Project Lead: Harry Sleeper (MITRE)  
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Project Team: Project Team Six – The MITRE Corporation, DPH Resources 
Approved: 1/30/2017 
Project Summary: The team hypothesizes that patterns exist in the timing and type of interactions 
preceding fatal and non-fatal overdose occurrences. Their objective is to identify patterns in the timing 
and type of interactions that precede fatal and non-fatal overdose occurrences. Interactions include 
those that occur with the healthcare and behavioral health systems, the criminal justice system, social 
services and other interactions that can be analyzed with the available data. The study plans to use most 
or all Chapter 55 data sets to examine complex interactions related to timing of events and subsequent 
fatal and non-fatal overdose. A dynamic model will be developed. Survival analyses and logistic 
regression will be used to define the states of change and the amount of change in the model. 
 
 
Project Title: Non-Fatal Overdoses, Differential Health Services Utilization, and Subsequent Risk 
Project Lead: Kimberley Geissler (UMASS Med)  
Project Team: Jennifer Whitehill (UMASS Med), Chelsea Young (UMASS Med), DPH Resources 
Approved: 1/30/2017 
Project Summary: Based on previous research examining substance use disorders, treatment after an 
initial non-fatal overdose is likely to vary based on insurance type (e.g., Medicaid, private insurance). 
Differences in treatment patterns may change the likelihood of repeat overdoses. We hypothesize that 
individuals with Medicaid insurance receive less treatment after an initial non-fatal overdose and are 
more likely to have a repeat overdose. Therefore, we will examine differences in repeat non-fatal and 
fatal overdoses among individuals with different insurance types after an initial non-fatal overdose.  
 
 
Project Title: A Machine Learning Approach to Identify Patients at Risk of Fatal and Non-Fatal Opiate 
Overdose  
Project Leads: Joscha Legewie (Yale) and Mathijs de Vaan (UC Berkeley) 
Project Team: Joscha Legewie (Yale) and Mathijs de Vaan (UC Berkeley), and DPH Resources 
Approved: 1/30/2017 
Project Summary: The objective of the analysis is to develop a predictive model based on PDMP that 
produces patient-level risk scores for opioid-related deaths and overdose. The key hypothesis is that 
consumption of prescription opioids captured in PDMP together with socio-demographic data is 
predictive of opioid-related deaths. This hypothesis is a pre-requirement for developing a risk score 
based on PDMP. We will use logistic regression and random forests as our initial models and experiment 
with other machine learning methods such as support vector machines, adaptive boosting and decision 
trees. Machine learning methods automate analytical model building and iteratively “learn” from data, 
which allows computers to find hidden patterns such as complex non-linearities or interactions. These 
non-linearities and interactions are particularly relevant for the case at hand considering the different 
pathways and likelihoods of transitioning into illicit drug use. This work may embed other machine 
learning models within the larger model (e.g., homelessness). The methods proposed in this study 
promise to significantly improve the prediction of fatal and non-fatal opioid overdose. Cross-validation 
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will be used to limit problems like overfitting and assess how the results of our model generalize to an 
independent data set. 
 
 
Project Title: Risk of Opioid Poisoning Associated with Medical Opioid Prescribing 
Project Leads: Laura Burke (BIDMC ) 
Project Team: Austin Frakt, Ashish Jha, and DPH Resources 
Approved: 1/30/2017 
Project Summary: Medical opioid prescribing is thought to play a key role in this trend and there has 
been concern that providers have had inadequate information about the risks of medical opioid. There 
are a number of studies in different settings looking at patient-level risk factors for an opioid poisoning 
(overdose). However, the absolute risk of an overdose for an individual receiving a new opioid 
prescription is not well characterized. Empirical evidence about the risk of poisoning is crucial for 
providers to better evaluate the risk-benefit profile of opioid treatment in patients with potential 
medical indications for opioid treatment. The objective of this analysis is to characterize the risk of 
opioid overdose for individuals receiving a new opioid prescription. 
 
 
Project Title: Risk of Overdose and Death after a Nonfatal Opioid Overdose 
Project Leads: Laura Burke (BIDMC)  
Project Team: Austin Frakt, Ashish Jha, and DPH Resources 
Approved: 1/30/2017 
Project Summary: There are a number of studies in different settings looking at patient-level risk factors 
for an opioid poisoning (overdose). However, more information is needed about the risk of death after a 
healthcare encounter for opioid overdose and the factors that mediate this risk. The objective of this 
analysis is to characterize the risk of subsequent death after a healthcare encounter (EMS, ED visit or 
hospitalization) for opioid poisoning and to understand individual demographic characteristics and co-
morbidities as well as indications for opioids that mediate the risk of death after a nonfatal overdose. 
 
 
Project Title: Receipt of Pharmacotherapy among Adolescents and Young Adults with Opioid Use 
Disorder and its Impact on Fatal and Non-Fatal Overdose 
Project Lead: Scott Hadland (BMC) 
Project Team: Sarah Bagley (BMC), Marc Larochelle (BMC), Alex Walley (BMC), and DPH Resources 
Approved: 1/30/2017 
Project Summary: Despite preexisting clinical practice guidelines and a new policy statement from the 
American Academy of Pediatrics recommending pharmacotherapy for youth with OUD, no prior studies 
have examined the extent to which youth in Massachusetts receive medications (buprenorphine, 
naltrexone, or methadone) and how these medications reduce the likelihood of fatal and non-fatal 
overdose. The BMC team will address this knowledge gap by obtaining valid, precise, and up-to-date 
estimates of the percentage of youth receiving pharmacotherapy and relate this information to fatal and 
non-fatal events. They will also examine retention in care and rate of drug use relapse among youth 
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receiving pharmacotherapy. They will identify time trends and potential disparities in receipt of 
pharmacotherapy among youth with OUD in Massachusetts using the All Payers Claim Data (APCD), and 
measure retention in care and rates of drug use relapse among youth receiving pharmacotherapy. 
 
 
Project Title: Mortality of Patients who Received Pre-hospital Administration of Naloxone 
Project Lead: Scott Weiner (Harvard/BWH)  
Project Team: Sabrina Poon (Harvard/BWH), Olesya Baker (Partners), and DPH Resources  
Approved: 1/30/2017 
Project Summary: There has been significant emphasis on availability of naloxone for the lay public and 
prehospital administration as a means to prevent overdose death. Naloxone is now available as a 
standing order prescription from most commercial pharmacies, and by a special waiver, it can be 
administered by Basic Life Support medics. It is theorized that naloxone is saving a significant number of 
lives in the Commonwealth, but paradoxically, the opioid-related death rate continues to climb despite 
increased availability of naloxone. The purpose of this study is to determine the medium- and long-term 
mortality of patients who receive naloxone prehospital. The applicant hypothesizes that naloxone 
administration is a temporary life-saving measure for many patients, that >50% of patients who 
eventually died from an overdose had a previous episode of reversal with naloxone. 
 
 
Project Title: GIS, Spatial Epidemiological, and Geostatistical Analysis of Opioid Overdose in MA 
Project Lead: Tom Stopka (Tufts) 
Project Team: Kenneth Chui (Tufts), Anna Kaplan (Tufts), Rachel Hoh (Tufts), and DPH Resources 
Approved: 1/30/2017 
Project Summary: The study will characterize the geospatial distribution and clustering of non-fatal and 
fatal opioid overdose and its associated outcomes in MA. We will employ descriptive GIS mapping and 
hotspot cluster analyses that look to control for time, geography, and demographics as we work to 
portray the unfolding of the opioid epidemic in terms of deaths, non-fatal overdoses, and repeat 
overdoses in Massachusetts between 2011 and 2015. We will determine whether changes in the 
epidemic are related to relevant community-level factors to better understand the current state of the 
opioid epidemic and to project future patterns. 
 
 
Project Title: Examining Intervention Points to Reduce Fatal and Non-Fatal Opioid Overdoses in 
Massachusetts 
Project Lead: Tom Stopka (Tufts) 
Project Team: Marc LaRochelle (BMC), Adam Rose (RAND), Alex Walley (BMC), Kenneth Chui (Tufts), 
Anna Kaplan (Tufts), David Landy (Tufts), Rachel Hoh (Tufts) , and DPH Resources 
Approved: 1/30/2017 
Project Summary: This study will examine touchpoints to identify potential opioid use disorder (OUD) 
interventions in the health care delivery, criminal justice, and public health systems. We will identify 
distinct subpopulations, times, and venues for which potentially inappropriate prescribing (PIP) is 
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associated with fatal and non-fatal overdose. We will conduct spatial epidemiological analyses to 
characterize the geographic distribution and clustering of PIP, touchpoints before overdose events, non-
fatal and fatal overdoses, and access to OUD services across Massachusetts (MA). 
 
  
Project Title: Opioid Prescription and Utilization after Orthopedic Surgery 
Project Lead: Brandon Earp (BIDMC) 
Project Team: Ariana Mora (BIDMC), Praveen Murthy (BIDMC), Jamie Collins (BIDMC), Philip Blazar 
(BIDMC), and DPH Resources 
Approved: March 6, 2017 
Project Summary: The purpose of this study is to identify the incidence and risk factors for prolonged 
use or misuse of opioids, opioid overdose, and opioid-related mortality in patients who have undergone 
orthopedic procedures in different orthopedic subspecialties. Understanding the characteristics of these 
patients and their prescribers will facilitate development of future protocols that minimize early opioid 
dependence after orthopedic surgery, and thereby minimize the risk of long-term opioid-related 
morbidity and mortality. We hypothesize that there is a substantial and underestimated incidence of 
prolonged post-operative opioid use beyond the initial perioperative period, and that there are 
identifiable risk factors that predispose to ongoing prescription opioid use in this population, including 
both patient factors and prescriber factors listed below. 
 
 
Project Title: Effect of treatment for opioid use disorder on opioid-related death among patients with 
intravenous drug associated endocarditis 
Project Lead: Simeon Kimmel (BMC) 
Project Team: Alex Walley (BMC), Ben Linas (BMC), Marc LaRochelle (BMC), and DPH Resources 
Approved: March 6, 2017 
Project Summary: In this analysis, we will define the effect of medications for opioid use disorder on 
opioid related mortality in intravenous drug associated endocarditis (IE-IDU). Reporting the number of 
patients in Massachusetts with IE-IDU who receive recommended treatment for opioid use disorder 
after an episode of endocarditis will add to our understanding of the current opioid epidemic. 
Moreover, describing the impact of treatment for underlying opioid use on overdose and overall 
mortality can guide public health and clinical strategies to improve mortality in this high-risk population. 
Treatment with medication for opioid use disorder (MOUD) in patients with injection drug associated 
endocarditis is associated with reduced opioid-related and all-cause mortality utilization and opioid 
overdose among families involved in the Emergency Assistance (EA) shelter system 
 
 
Project Title: Assessing the relationship between patterns of shelter and behavioral health services 
utilization and opioid overdose among families involved in the Emergency Assistance (EA) shelter system 
Project Lead: Thomas Byrne (BU)  
Project Team: Margaret Thomas (BU), Daniel Miller (BU), Yoonsook Ha (BU), Travis Baggett (BHCFH) , 
and DPH Resources 
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Project Summary: The proposed project seeks to assess the extent to which, among families using the 
Emergency Assistance (EA) shelter system, different patterns of shelter and behavioral health services 
utilization are associated with the risk of fatal and non-fatal opioid overdose. . The project is motivated 
by prior research demonstrating that heads of households in families that make episodic (i.e. multiple 
discrete episodes over time) use of EA shelter have higher rates of substance abuse and mental health 
treatment histories than do their counterparts in families that make either transitional (i.e. a single, brief 
episode) or long term (i.e. a single extended episode) use of EA shelter. By assessing whether such 
variation in shelter utilization and behavioral health services use is associated with opioid overdose, the 
project stands to provide actionable information that could be used to help prevent future overdoses 
among EA-involved families. Specifically, findings could be used to inform the development of a tool that 
would identify EA-involved families who may be appropriate candidates for targeted screening and 
intervention efforts. 
 
 
Project Title: Understanding the Impact that Mental Health has on the Likelihood of Opiate Addiction, 
Overdose, and Death 
Project Lead: Christer Johnson (Ernst & Young)  
Project Team: Ankur Jindal (Ernst & Young), Debra Cammer Hines (Ernst & Young), and DPH Resources 
Project Summary: Much of the analytical focus in creating insights to reduce the number of opiate 
related overdoses and deaths has been focused on medical claim and prescription data, but very little 
focus has been given to behavioral health claims associated with mental health diagnosis and treatment. 
We propose to use exploratory data mining techniques to examine the relationship between a patient’s 
mental health diagnosis and treatment history and opiate abuse and overdose. This analysis will allow us 
to create a patient risk profile for opiate abuse which can be used to inform treatment plans and help 
health care providers identify patients who are good candidates for interventions before they become 
addicted and thus prevent opiate related overdose and death 
 
 
Project Title: Benzodiazepines, ADHD stimulants and overdose in buprenorphine maintenance 
treatment 
Project Lead: Tae Woo Park (BMC)  
Project Team: Marc LaRochelle (BMC), Alex Walley (BMC) , and DPH Resources 
Project Summary: Benzodiazepines (BZD) and ADHD stimulants are commonly prescribed for psychiatric 
co-morbidities in patients receiving buprenorphine maintenance treatment (BMT). BZD and stimulant-
related poisoning deaths have increased in the US. No large epidemiological study has tested the 
association between BZD or stimulants and fatal or non-fatal overdose in people receiving BMT. 
Additionally, the benefits of BZD or stimulants in the BMT patient population are largely unknown. 
Prescribing BZD or stimulants may increase patient adherence to BMT (see BZD maintenance treatment 
studies in methadone maintenance) and thus decrease risk of overdose. The study will focus on two 
primary questions. Is receipt of BZD or stimulant associated with BMT treatment retention? Is the 
relationship between BZD or stimulant and OD mediated by BMT treatment retention? 
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Project Title: Assessing Racial Differences In Accessing Treatment Subsequent To A Non-fatal Opioid 
Overdose Related Hospital Patient Encounter 
Project Lead: Dan Dooley (BPHC)  
Project Team: Snehal Shah (BPHC), and DPH Resources 
Project Summary: Our purpose is to gain a better understanding of the relationship between opioid-
related hospital care and subsequent substance abuse treatment admissions. Specifically, we seek to 
assess whether race and other factors in the hospital record predict follow-up substance abuse 
treatment among individuals who experienced a non-fatal opioid overdose. To determine if and to the 
what extent there are racial/ethnic differences in the rates of individual residents receiving subsequent 
substance abuse treatment services among those who have received acute hospital care for non-fatal 
opioid overdose and for any substance abuse-related diagnosis within the prior month and to assess 
factors within the Case Mix record that may play a role in predicting direct follow-up to treatment 
services. 
 
 
Project Title: Defining the cascade of care for substance use disorder detoxification in Massachusetts 
Project Lead: Jake Morgan (BU)  
Project Team: Josh Barocas (BU), Ben Linas (BU), Jenny Wang (BU), Alex Walley (BMC), Jenifer Jaeger 
(BPHC) , and DPH Resources 
Project Summary: The goal of this project is to describe the cascade of care and churn (i.e., frequent 
relapse and readmission) in substance use disorder (SUD) treatment in Massachusetts for those entering 
acute treatment services (ATS, detoxification) to inform policies to reduce the risk of fatal and non-fatal 
opioid overdoses in the Commonwealth. We will describe the movement from ATS post-detox 
treatment (lower levels of care including CSS and TSS) to longer term residential services, and to 
outpatient treatment such as outpatient based opioid treatment (OBOT), describing relapse associated 
with each treatment level and transition (time between treatment services) as well as the rate of 
successful transitions to lower levels of care. The flexibility of our model will incorporate the variety of 
paths from ATS through the cascade, and we will describe the impact of each point in the cascade on 
fatal and non-fatal opioid-related overdose outcomes. 
 
 
Project Title: Community Distribution of Naloxone Kits and Naloxone Rescues 
Project Lead: Alex Walley (BMC) 
Project Team: Traci Green (Brown), Tom Stopka (Tufts), Marc Larochelle (BMC), Na Wang (BMC), and 
DPH Resources 
Project Summary: Community overdose response with naloxone is one of the core strategies identified 
by the US Department of Health and Human Services to address the opioid epidemic. The 
Massachusetts’ Governor’s Opioid Working Group identified access to naloxone as a key strategy to 
addressing the opioid crisis. Massachusetts is an early adopter of community overdose education and 
naloxone distribution. The objectives of this analysis are to use the Chapter 55 databases to generate 
the amount of naloxone distributed to the community per community (municipality, zip code) over time 
and the amount of naloxone administered by community members during rescue attempts per 
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community per month. A secondary objective of the project is to assess the geospatial distribution of 
naloxone, as well as rescue attempts, by zip code. This project will generate community level rates of 
naloxone distribution and naloxone rescue attempts from multiple sources linked through the chapter 
55 databases. 
 
 
Project Title: Iatrogenic Opioid Addiction and Overdose in Orthopaedic Trauma: Examining a Natural 
Experiment 
Project Lead: Matthew Basilico (Harvard) 
Project Team: Abhiram Bhashyam (Harvard), Marilyn Heng (Harvard), Alan Xie (Harvard), Chethan 
Bachireddy (Harvard), and DPH Resources 
Project Summary: This natural experiment utilizes the insight that clinicians differ in their individual 
propensities to prescribe a particular treatment course among many available options.  To identify the 
relationship between opioid prescribing and addiction, they will use the econometric technique of 
“instrumental variables,” and use first-year resident assignment as the discharging clinician in 
orthopedic trauma surgery as an “instrument”—a feature that is essentially random in its assignment—
for the opioid prescription the patient receives.  For comparison, they will also utilize two additional 
instruments, differing levels of trauma severity in a motor vehicle accidents, and facility-level 
propensities to refer to medication assisted treatment after discharge, as well as predictive techniques 
from machine learning to give context to our causal estimates. 
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Appendix D Section 2: Full-sized maps of opioid overdose death rates by year. 
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Appendix D Section 3: Community Quintile Scores (Alphabetical Order) 
 
Community Quintile116 Community Quintile Community Quintile 
Abington 1 Braintree 2 Dudley 3 
Acton 4 Brewster 3 Dunstable 4 
Acushnet 2 Bridgewater 2 Duxbury 5 
Adams 1 Brimfield 2 East Bridgewater 1 
Agawam 2 Brockton 1 East Brookfield 3 
Alford 2 Brookfield 3 East Longmeadow 2 
Amesbury 2 Brookline 5 Eastham 1 
Amherst 5 Buckland 4 Easthampton 2 
Andover 4 Burlington 3 Easton 3 
Aquinnah 2 Cambridge 4 Edgartown 5 
Arlington 4 Canton 3 Egremont 4 
Ashburnham 4 Carlisle 5 Erving 2 
Ashby 3 Carver 1 Essex 5 
Ashfield 5 Charlemont 3 Everett 1 
Ashland 4 Charlton 3 Fairhaven 2 
Athol 1 Chatham 4 Fall River 1 
Attleboro 2 Chelmsford 4 Falmouth 1 
Auburn 3 Chelsea 1 Fitchburg 1 
Avon 1 Cheshire 5 Florida 5 
Ayer 1 Chester 4 Foxborough 3 
Barnstable 1 Chesterfield 4 Framingham 2 
Barre 1 Chicopee 1 Franklin 3 
Becket 4 Chilmark 3 Freetown 2 
Bedford 4 Clarksburg 4 Gardner 1 
Belchertown 3 Clinton 1 Georgetown 4 
Bellingham 3 Cohasset 3 Gill 3 
Belmont 5 Colrain 5 Gloucester 1 
Berkley 2 Concord 5 Goshen 4 
Berlin 5 Conway 4 Gosnold 5 
Bernardston 1 Cummington 3 Grafton 3 
Beverly 2 Dalton 4 Granby 3 
Billerica 2 Danvers 2 Granville 4 
Blackstone 4 Dartmouth 2 Great Barrington 4 
Blandford 3 Dedham 2 Greenfield 1 
Bolton 4 Deerfield 4 Groton 4 
Boston 1 Dennis 1 Groveland 4 
Bourne 1 Dighton 4 Hadley 4 
Boxborough 5 Douglas 3 Halifax 2 
Boxford 5 Dover 5 Hamilton 4 
Boylston 3 Dracut 2 Hampden 3 
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 Lower quintiles indicate highest relative burden. Higher quintiles indicate lowest relative burden. 
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Community Quintile Scores (Alphabetical Order) 
 
Community Quintile117 Community Quintile Community Quintile 
Hancock 5 Ludlow 2 New Bedford 1 
Hanover 3 Lunenburg 2 New Braintree 2 
Hanson 2 Lynn 1 New Marlborough 5 
Hardwick 2 Lynnfield 3 New Salem 3 
Harvard 5 Malden 1 Newbury 4 
Harwich 1 Manchester 5 Newburyport 4 
Hatfield 2 Mansfield 4 Newton 5 
Haverhill 1 Marblehead 5 Norfolk 4 
Hawley 5 Marion 3 North Adams 1 
Heath 4 Marlborough 3 North Andover 4 
Hingham 5 Marshfield 2 North Attleboro 3 
Hinsdale 3 Mashpee 1 North Brookfield 3 
Holbrook 1 Mattapoisett 3 North Reading 3 
Holden 3 Maynard 3 Northampton 1 
Holland 3 Medfield 5 Northborough 5 
Holliston 4 Medford 2 Northbridge 1 
Holyoke 1 Medway 5 Northfield 2 
Hopedale 3 Melrose 2 Norton 2 
Hopkinton 4 Mendon 4 Norwell 3 
Hubbardston 2 Merrimac 4 Norwood 2 
Hudson 2 Methuen 2 Oak Bluffs 4 
Hull 1 Middleborough 1 Oakham 4 
Huntington 3 Middlefield 2 Orange 1 
Ipswich 3 Middleton 4 Orleans 3 
Kingston 4 Milford 3 Otis 4 
Lakeville 2 Millbury 1 Oxford 2 
Lancaster 2 Millis 5 Palmer 1 
Lanesborough 3 Millville 5 Paxton 3 
Lawrence 1 Milton 4 Peabody 2 
Lee 2 Monroe 5 Pelham 5 
Leicester 2 Monson 3 Pembroke 2 
Lenox 4 Montague 2 Pepperell 2 
Leominster 1 Monterey 5 Peru 5 
Leverett 5 Montgomery 5 Petersham 3 
Lexington 5 Mount Washington 5 Phillipston 4 
Leyden 5 Nahant 3 Pittsfield 1 
Lincoln 5 Nantucket 3 Plainfield 5 
Littleton 5 Natick 4 Plainville 3 
Longmeadow 5 Needham 5 Plymouth 2 
Lowell 1 New Ashford 3 Plympton 2 
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 Lower quintiles indicate highest relative burden. Higher quintiles indicate lowest relative burden. 
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Community Quintile Scores (Alphabetical Order) 
 
Community Quintile118 Community Quintile Community Quintile 
Princeton 2 Springfield 1 West Boylston 3 
Provincetown 4 Sterling 5 West Bridgewater 1 
Quincy 1 Stockbridge 3 West Brookfield 3 
Randolph 2 Stoneham 2 West Newbury 5 
Raynham 1 Stoughton 1 West Springfield 1 
Reading 3 Stow 5 West Stockbridge 4 
Rehoboth 5 Sturbridge 4 West Tisbury 5 
Revere 1 Sudbury 5 Westborough 4 
Richmond 2 Sunderland 4 Westfield 2 
Rochester 5 Sutton 4 Westford 5 
Rockland 1 Swampscott 3 Westhampton 5 
Rockport 3 Swansea 2 Westminster 3 
Rowe 5 Taunton 1 Weston 5 
Rowley 4 Templeton 2 Westport 3 
Royalston 2 Tewksbury 2 Westwood 5 
Russell 4 Tisbury 3 Weymouth 1 
Rutland 4 Tolland 5 Whately 5 
Salem 1 Topsfield 4 Whitman 1 
Salisbury 1 Townsend 2 Wilbraham 4 
Sandisfield 5 Truro 2 Williamsburg 5 
Sandwich 3 Tyngsborough 3 Williamstown 5 
Saugus 1 Tyringham 3 Wilmington 2 
Savoy 4 Upton 5 Winchendon 1 
Scituate 2 Uxbridge 2 Winchester 5 
Seekonk 5 Wakefield 2 Windsor 4 
Sharon 4 Wales 3 Winthrop 1 
Sheffield 4 Walpole 4 Woburn 1 
Shelburne 2 Waltham 3 Worcester 1 
Sherborn 5 Ware 1 Worthington 4 
Shirley 3 Wareham 1 Wrentham 4 
Shrewsbury 4 Warren 2 Yarmouth 1 
Shutesbury 4 Warwick 5     
Somerset 2 Washington 5     
Somerville 2 Watertown 3     
South Hadley 2 Wayland 5     
Southampton 3 Webster 1     
Southborough 5 Wellesley 5     
Southbridge 1 Wellfleet 1     
Southwick 3 Wendell 4     
Spencer 1 Wenham 5     
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 Lower quintiles indicate highest relative burden. Higher quintiles indicate lowest relative burden. 
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Community Quintile Scores (Quintile 1: Highest Relative Burden) 
 
Community Quintile119 Community Quintile Community Quintile 
Abington 1 Greenfield 1 Rockland 1 
Adams 1 Harwich 1 Salem 1 
Athol 1 Haverhill 1 Salisbury 1 
Avon 1 Holbrook 1 Saugus 1 
Ayer 1 Holyoke 1 Southbridge 1 
Barnstable 1 Hull 1 Spencer 1 
Barre 1 Lawrence 1 Springfield 1 
Bernardston 1 Leominster 1 Stoughton 1 
Boston 1 Lowell 1 Taunton 1 
Bourne 1 Lynn 1 Ware 1 
Brockton 1 Malden 1 Wareham 1 
Carver 1 Mashpee 1 Webster 1 
Chelsea 1 Middleborough 1 Wellfleet 1 
Chicopee 1 Millbury 1 West Bridgewater 1 
Clinton 1 New Bedford 1 West Springfield 1 
Dennis 1 North Adams 1 Weymouth 1 
East Bridgewater 1 Northampton 1 Whitman 1 
Eastham 1 Northbridge 1 Winchendon 1 
Everett 1 Orange 1 Winthrop 1 
Fall River 1 Palmer 1 Woburn 1 
Falmouth 1 Pittsfield 1 Worcester 1 
Fitchburg 1 Quincy 1 Yarmouth 1 
Gardner 1 Raynham 1 
  Gloucester 1 Revere 1 
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 Lower quintiles indicate highest relative burden. Higher quintiles indicate lowest relative burden. 
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Community Quintile Scores (Quintile 2: Higher Than Average Relative Burden) 
 
Community Quintile120 Community Quintile Community Quintile 
Acushnet 2 Hardwick 2 Plymouth 2 
Agawam 2 Hatfield 2 Plympton 2 
Alford 2 Hubbardston 2 Princeton 2 
Amesbury 2 Hudson 2 Randolph 2 
Aquinnah 2 Lakeville 2 Richmond 2 
Attleboro 2 Lancaster 2 Royalston 2 
Berkley 2 Lee 2 Scituate 2 
Beverly 2 Leicester 2 Shelburne 2 
Billerica 2 Ludlow 2 Somerset 2 
Braintree 2 Lunenburg 2 Somerville 2 
Bridgewater 2 Marshfield 2 South Hadley 2 
Brimfield 2 Medford 2 Stoneham 2 
Danvers 2 Melrose 2 Swansea 2 
Dartmouth 2 Methuen 2 Templeton 2 
Dedham 2 Middlefield 2 Tewksbury 2 
Dracut 2 Montague 2 Townsend 2 
East Longmeadow 2 New Braintree 2 Truro 2 
Easthampton 2 Northfield 2 Uxbridge 2 
Erving 2 Norton 2 Wakefield 2 
Fairhaven 2 Norwood 2 Warren 2 
Framingham 2 Oxford 2 Westfield 2 
Freetown 2 Peabody 2 Wilmington 2 
Halifax 2 Pembroke 2   
Hanson 2 Pepperell 2   
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 Lower quintiles indicate highest relative burden. Higher quintiles indicate lowest relative burden. 
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Community Quintile Scores (Quintile 3: Average Relative Burden) 
 
Community Quintile121 Community Quintile Community Quintile 
Ashby 3 Hampden 3 Orleans 3 
Auburn 3 Hanover 3 Paxton 3 
Belchertown 3 Hinsdale 3 Petersham 3 
Bellingham 3 Holden 3 Plainville 3 
Blandford 3 Holland 3 Reading 3 
Boylston 3 Hopedale 3 Rockport 3 
Brewster 3 Huntington 3 Sandwich 3 
Brookfield 3 Ipswich 3 Shirley 3 
Burlington 3 Lanesborough 3 Southampton 3 
Canton 3 Lynnfield 3 Southwick 3 
Charlemont 3 Marion 3 Stockbridge 3 
Charlton 3 Marlborough 3 Swampscott 3 
Chilmark 3 Mattapoisett 3 Tisbury 3 
Cohasset 3 Maynard 3 Tyngsborough 3 
Cummington 3 Milford 3 Tyringham 3 
Douglas 3 Monson 3 Wales 3 
Dudley 3 Nahant 3 Waltham 3 
East Brookfield 3 Nantucket 3 Watertown 3 
Easton 3 New Ashford 3 West Boylston 3 
Foxborough 3 New Salem 3 West Brookfield 3 
Franklin 3 North Attleboro 3 Westminster 3 
Gill 3 North Brookfield 3 Westport 3 
Grafton 3 North Reading 3   
Granby 3 Norwell 3   
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 Lower quintiles indicate highest relative burden. Higher quintiles indicate lowest relative burden.  
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Community Quintile Scores (Quintile 4: Lower Than Average Relative Burden) 
 
Community Quintile122 Community Quintile Community Quintile 
Acton 4 Granville 4 Phillipston 4 
Andover 4 Great Barrington 4 Provincetown 4 
Arlington 4 Groton 4 Rowley 4 
Ashburnham 4 Groveland 4 Russell 4 
Ashland 4 Hadley 4 Rutland 4 
Becket 4 Hamilton 4 Savoy 4 
Bedford 4 Heath 4 Sharon 4 
Blackstone 4 Holliston 4 Sheffield 4 
Bolton 4 Hopkinton 4 Shrewsbury 4 
Buckland 4 Kingston 4 Shutesbury 4 
Cambridge 4 Lenox 4 Sturbridge 4 
Chatham 4 Mansfield 4 Sunderland 4 
Chelmsford 4 Mendon 4 Sutton 4 
Chester 4 Merrimac 4 Topsfield 4 
Chesterfield 4 Middleton 4 Walpole 4 
Clarksburg 4 Milton 4 Wendell 4 
Conway 4 Natick 4 West Stockbridge 4 
Dalton 4 Newbury 4 Westborough 4 
Deerfield 4 Newburyport 4 Wilbraham 4 
Dighton 4 Norfolk 4 Windsor 4 
Dunstable 4 North Andover 4 Worthington 4 
Egremont 4 Oak Bluffs 4 Wrentham 4 
Georgetown 4 Oakham 4   
Goshen 4 Otis 4   
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 Lower quintiles indicate highest relative burden. Higher quintiles indicate lowest relative burden. 
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Community Quintile Scores (Quintile 5: Lowest Relative Burden) 
 
Community Quintile123 Community Quintile Community Quintile 
Amherst 5 Lincoln 5 Seekonk 5 
Ashfield 5 Littleton 5 Sherborn 5 
Belmont 5 Longmeadow 5 Southborough 5 
Berlin 5 Manchester 5 Sterling 5 
Boxborough 5 Marblehead 5 Stow 5 
Boxford 5 Medfield 5 Sudbury 5 
Brookline 5 Medway 5 Tolland 5 
Carlisle 5 Millis 5 Upton 5 
Cheshire 5 Millville 5 Warwick 5 
Colrain 5 Monroe 5 Washington 5 
Concord 5 Monterey 5 Wayland 5 
Dover 5 Montgomery 5 Wellesley 5 
Duxbury 5 Mount Washington 5 Wenham 5 
Edgartown 5 Needham 5 West Newbury 5 
Essex 5 New Marlborough 5 West Tisbury 5 
Florida 5 Newton 5 Westford 5 
Gosnold 5 Northborough 5 Westhampton 5 
Hancock 5 Pelham 5 Weston 5 
Harvard 5 Peru 5 Westwood 5 
Hawley 5 Plainfield 5 Whately 5 
Hingham 5 Rehoboth 5 Williamsburg 5 
Leverett 5 Rochester 5 Williamstown 5 
Lexington 5 Rowe 5 Winchester 5 
Leyden 5 Sandisfield 5   
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 Lower quintiles indicate highest relative burden. Higher quintiles indicate lowest relative burden. 
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Appendix E: Legal Agreements 
 
In order to meet the legal requirements of working with all of these protected datasets, a number of 
legal documents were produced. Four different types of agreements were signed. 
 
1) Linking – This agreement between DPH and Center for Health Information and Analysis (CHIA) 
allowed for the exchange of data for the purposes of securely connecting data at the individual 
level across secure datasets without exposing the identity of the individual so connected. 
2) Sharing – This agreement outlined the methodology and restrictions allowing for the sharing of 
data between different departments or agencies that were not previously sharing – or even 
allowed to share, outside of the Chapter 55 project. Each of the data-supplying entities was a 
signatory to this ISA. Specifically, signatories include: the Department of Public Health (DPH), the 
Department of Correction (DOC), the Executive Office of Public Safety and Security (EOPSS) for 
Houses of Correction data (HOC), the Office of the Chief Medical Examiner (OCME), the 
Department of Veterans’ Services (DVS), the Department of Mental Health (DMH), the 
Department of Housing and Community Development (DHCD), MassHealth, and the Center for 
Health Information and Analysis (CHIA). While CHIA has previously signed the Linking 
agreement, they are also the provider of analytic data from the All Payer Claims Database 
(APCD) and Case Mix. 
3) Hosting – An agreement between DPH and MassIT specifying the hosting responsibilities and 
restrictions for the data infrastructure. 
4) Access – An additional agreement created for ad hoc access to data outside of the purview of 
the prior three agreements. For example: If the Data Office within MassIT were to assist in a way 
that required analytical data access that is not covered by the 3rd agreement (which is hosting 
specific). This 4th agreement essentially outlines the responsibilities of being a good data 
steward and requires a signature for access. There would conceivably be n number of these 
agreements signed over time. 
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Appendix F:  Partnerships  
 
The Chapter 55 project brought together analysts and researchers from across government, more than a 
dozen academic institutions, and two private consulting firms.  First and foremost, the Department of 
Public Health would like to thank all those who participated in this effort.  Without everyone’s 
assistance, this report could not have been completed in time.  The work done here has been 
groundbreaking and the collaboration has been extraordinary both inside and outside government 
institutions.  
 
 
State Agencies 
 Center for Health Information and Analysis  
 EOHHS IT  
 EOPSS 
 Department of Correction  
 Department of Housing and Community Development  
 Department of Mental Health  
 Department of Public Health  
 Department of Veterans’ Services  
 Massachusetts Sheriffs’ Association 
 Massachusetts State Police 
 MassHealth  
 Mass IT – Data Office 
 Office of the Chief Medical Examiner 
Academic Institutions and Private Industry 
 Beth Israel Deaconess Hospital 
 Boston Children’s Hospital Boston Health Care for the 
Homeless 
 Boston Medical Center 
 Boston Public Health Commission 
 Boston University School of Medicine 
 Brigham & Women’s Hospital 
 Brown University 
 Center for Social Innovation 
 Centers for Disease Control and Prevention 
 Commonwealth Medicine 
 Ernst & Young 
 General Electric Foundation 
 Harvard Medical School 
 Harvard School of Public Health 
 Harvard University 
 Mass College of Pharmacy and Health Sciences  
 Massachusetts Institute of Technology 
 MITRE Corporation 
 Northeastern University 
 Partners Healthcare 
 Price Waterhouse Cooper 
 RAND Corporation 
 SAS Analytics  
 Tufts University School of Medicine 
 University of Massachusetts, Amherst 
 University of Massachusetts, Boston 
 University of Massachusetts Medical School 
 University of California, Berkeley  
 Veterans Administration  
 Yale University 
